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 ABSTRACT 
 
 
Background 
Muscle cramps are one of the adverse affects suffered by hypercholesterolemia patients 
who are treated with statins. Besides reducing cholesterol levels, statins also reduce 
coenzyme Q10 (CoQ10) blood levels. One of several hypotheses of pathophysiology for 
statin-induced muscle cramps is reduced level of CoQ10. Besides being a very important 
antioxidant, CoQ10 also functions as a transmembrane proton conductor and an electron 
carrier between NADH and succinate dehydrogenases and the cytochrome system, 
which is needed for phosphorylation of ADP into ATP. Therefore, a decrease in the 
CoQ10 tissue levels, as reflected in its reduced blood levels, may contribute to the 
muscle function impairment. Researchers have proven that statins, drugs used to lower 
cholesterol, are able to reduce CoQ10 blood levels.  
 
Null Hypothesis 
The administration of CoQ10 will have no effect on the frequency, severity and/or 
duration of muscle cramps amongst statin users. 
 
Aims 
This study aimed to assess factors that might influence the development of statin-
induced myopathy manifested as muscle cramps, including the respondent’s age and 
sex; the dose and duration of their statin therapy; muscle symptoms (nature, duration and 
whether or not they have changed with statin use); other medicines consumed; and, other 
diseases suffered and to investigate the efficacy of oral CoQ10 supplements in reducing 
muscle cramps in statin users and non-users. 
 
Methods 
The Study was comprised of two phases: Phase 1 the Muscle Adverse Effect Survey and 
Phase 2 the Coenzyme Q10 for Muscle Cramps Study. Data collection for Phase 1 took 
place from January 2006 to April 2006 in 45 community pharmacies throughout 
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Western Australia. The second phase of the study, the clinical trial, took place through 
School of Pharmacy, Curtin University of Technology, from May 2006 to December 
2006. 
 
Results 
In the first phase of the study, the Muscle Adverse Effect Survey, it was found that the 
prevalence of myopathy amongst statin users was 22.3% (205/920). Amongst the 
respondents with muscle symptoms, 73/205 (35.6%) reported their muscle symptoms 
had worsened on using statins. Assuming non-respondents did not suffer from muscle 
problems reduced the overall incidence of potential statin-induced myopathy to 73/920 
or 7.93%. It was found that atorvastatin was the most commonly prescribed statin 
(59.3%), followed by simvastatin (29.8%), then pravastatin (10.4%) and fluvastatin 
(0.6%). Despite the high use of atorvastatin, the incidence rate of myopathy by 
atorvastatin users was found to be similar with other statins. The most common muscle 
symptoms were night cramps (54.6%), muscle aching (52.7%), and fatigue (49.3%), 
while the most commonly affected area of the body was the calves (62%).  
 
Statistical analysis with multiple logistic regression showed increasing age, heart failure 
and the use of cortisone-like drugs increased the risk of muscle symptoms among statin 
users. It was found that, for every 1-year increase in age, the odds of suffering from 
muscle symptoms increased 1.039 (95% CI 1.019 – 1.061).  Furthermore, taking 
cortisone-like medication increased the odds of suffering muscle symptoms 16.4 times 
(95% CI; 2.2 – 124.3), while participants with heart failure were 9.3 times (95% CI 1.2 – 
73.2) more likely to develop muscle symptoms when prescribed statins. 
 
The second phase of the study, the Coenzyme Q10 for Muscle Cramps Study, was a 
single blind, placebo-controlled, cross over, 6-week evaluation of the benefits CoQ10 in 
reducing muscle cramps amongst statin users and non-users. It was found that on 
average, that statin users experienced a significant reduction in the severity of their 
muscle cramps, as indicated by lower average pain scores, during the period they were 
on CoQ10 (6.36 ± 0.75) compared with placebo (7.37 ± 0.85; p = 0.028). Furthermore, 
 vi
patients also experienced significantly shorter cramp duration when they were on CoQ10 
(4.88 ± 0.84) than on placebo (5.84 ± 0.84; p = 0.001). In contrast, amongst non-statin 
users (who were used as controls), there were no significant differences between CoQ10 
and placebo efficacy in all assessed variables. 
 
Conclusion 
This study revealed that muscle symptoms were common among statin users, 
particularly those suffering from heart failure, taking corticosteroids, and increasing age. 
Furthermore, the administration of CoQ10 100 mg per day was safe and effective in 
reducing severity and duration of muscle cramps amongst statin users. However, these 
later findings need to be confirmed by larger, double blind, placebo controlled studies. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
 
1.1 MUSCLE CRAMPS 
1.1.1 Definition of Muscle Cramps 
The aetiology of the cramp can most likely to be traced to “cram”, from Old High 
German and Norse roots that means squeezing, pressing, or pinching uncomfortably1. 
Muscle cramps can be defined as an involuntarily, painful contraction of muscle, lasting 
seconds to minutes, often with a palpable hard knot in the affected muscle1-8. These 
cramps are painful and electromyographically show a raised frequency of motor unit 
potentials that spread throughout the muscles and result in a sustained muscle 
contraction (an electromyogram (EMG) measures this repetitive firing of motor unit 
potentials up to 150 per second) 1, 4. The pain occurring may result from the 
accumulation of toxic metabolites or possibly the result of local ischaemia2. The calf is 
the most commonly affected, but cramps in the finger and hands also occur in 30% of 
patients2, 4, 9. Further details of clinical features of muscle cramps are summarized on 
Table 1.11, 6. 
 
Table 1.1 Clinical features of muscle cramps1, 6 
Cramp symptoms  
Acutely painful and may result in persistent soreness, swelling, and with elevated 
serum CK (48-72 hours) 
Occur as explosive onset and variable rate of improvement, with visible and palpable 
contraction. 
Occur usually in one muscle or part of a muscle  
Associated with both trivial movements and forceful contraction (especially in already 
shortened muscle) 
Start and end with EMG evidence of muscle twitching that waxes and wanes 
independently in different part of the muscles. 
Stretching the muscle terminates cramps. 
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These features in Table 1.1 can be used to differentiate other muscle problems, such as 
myalgia, myositis and myotonia, since involuntary muscle contractions are not observed 
in disorders such as myalgia or myositis, and pain is not featured in myotonia. Another 
disorder, called contracture (such as writer’s cramps), also occurs involuntarily but is 
totally electrically silent (EMG-free activity). Involuntarily muscle contractions also 
occur in dystonia, where contractions of agonist and antagonist muscle groups lead to 
body contortions, and in tetany, where the generalized contractions result from both 
diffuse motor activity and sensory disturbances1, 4 (Table 1.24). 
 
Table 1.2 Muscle cramps and muscle cramp-like phenomena4 
Term Definition 
“True muscle cramps” An involuntary, painful contraction associated with an 
increased frequency of motor unit action potentials 
Dystonia Simultaneous contraction of both agonist and antagonist 
muscle  
Muscle contracture An involuntary state of sustained muscle contraction that 
is electrically silent, and there is inability of muscle fibres 
to undergo relaxation 
Tetany A syndrome of sensory and motor neuron 
hyperexcitability, with resultant motor and sensory 
hyperactivities 
 
 
1.1.2 Prevalence of Muscle Cramps 
The proportion of cramps suffered may vary across the population. Miller and Layer in 
their review1 noted that the prevalence of muscle cramps could be as high as 95% among 
a group of young students recently enrolled in an exercise class1. Other studies revealed 
that the prevalence of cramps in elderly people was between 35%-60%, with 40% of 
elderly people reporting having cramps more than three times a week in one study, and 
6% reporting daily cramps2. Another study of 350 elderly patients found that 50% of 
them suffered from nocturnal leg cramps, with 20% reporting symptoms for 10 years or 
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more10. It has also been reported that one-third of the Dutch adult population had at least 
one muscle cramp a year, and 2% suffer from muscle cramps every week11.  
 
 
1.1.3 Pathophysiology of Muscle Cramps 
 
There are two main views about the pathophysiology of muscle cramps. The first theory 
proposes that muscle cramps result from spontaneous discharges of the motor nerves1, 6, 
12, while the second theory tends to suggest that cramps result from within the muscle 
itself3. Those who support the first theory 1, 6, 12 argue that involuntary repetitive firing of 
motor unit action potentials at very high frequency, which happens during cramps, is 
more likely to represent spontaneous neuron motor activity rather than muscle activity. 
They also argue that a cramp is often preceded and accompanied by fasciculation in the 
same muscle, which is notably demonstrated at the beginning and the end of cramps on 
EMG.  
 
On the other hand, Roeleveld et al3, who favour the second theory, point out that single 
muscle fibers are capable of manifesting repetitive discharges independently. They also 
argue that neurogenic origin theory is only based on observation that cramps may occur 
in individuals without obvious pathophysiology and that cramps cannot be induced after 
the administration of curare. In their study3, it was found that cramps present as slowly 
moving fraction of muscle fibres that indicate that either the spatial arrangement of the 
motoneurons and muscle fibres are highly related, or that cramps are initiated close to or 
even at the muscle fibre level. 
 
 
1.1.4 Aetiology of Muscle Cramps 
Muscle cramps notably occur in certain metabolic disorders; following acute 
extracellular volume depletion; in diseases of the lower motor neuron; in hereditary 
disorders; as a side effect of medication; and may also occur without clear reasons1, 6 
(Table 1.3). 
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Table 1.3 Aetiology of cramps1, 4 
Aetiology of cramps Examples 
No apparent cause Nocturnal leg cramps 
Exercise-related cramps 
Lower motor neuron disorders Amyitropic lateral sclerosis 
After poliomyelitis 
Multifocal motor neuropathy 
Peripheral nerve injury 
Nerve root compression 
Polyneuropathies 
Metabolic disorders Pregnancy 
Uraemia 
Cirrhosis 
Hypothyroidsm 
Hypoadrenalism 
Acute extracellular volume depletion Perspiration or “heat cramps” 
Hemodialysis 
Diarrhoea 
Vomiting 
Hereditary disorders Autosomal-dominant inherited generalized 
muscle cramps 
Medications Statins (cholesterol-lowering medication) 
Beta-adrenergic agonists 
Donepezil 
Neostigmine 
Raloxifene 
Nifedipine 
Terbutaline 
Salbutamol 
Diuretics 
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1.1.4.1 Cramps with no apparent cause 
Nocturnal leg cramps typically involve the calf and foot, and are common in the elderly, 
but may also occur in any age of group. Although cramps are generally benign, they may 
cause considerable distress for patients as cramps frequently awaken patients from 
sleep1, 2, 6.  
 
Cramps also have been associated with exercise, especially with beginning a new 
exercise program. Even though cramps mostly occur after exercise, they may also occur 
during exercise, thus may limit performance. These exercise-associated cramps may be 
secondary to dehydration, electrolyte shifts or accumulation of metabolites in exercise 
muscles1, 2. 
 
 
1.1.4.2 Lower Motor Neuron Disorders 
A few diseases associated with the damage to the lower motor neuron are associated 
with cramps, including amyotrophic lateral sclerosis, recovered poliomyelitis, multifocal 
neuropathy, peripheral nerve injury, nerve root compression, and polyneuropathies. 
These disorders have similar symptoms, namely wasting of muscles, weakness, and 
evidence of denervation and reinervation on electrodiagnostic studies1, 6.    
 
In the case of recovered poliomyelitis (post polio syndrome), the severity of residual 
weakness, cramps and disability after acute poliomyelitis tends to predict the 
development of this disorder. Patients who had minimal symptoms from the original 
illness will most likely experience only mild post polio syndrome. Patients originally hit 
hard by poliovirus are more likely to develop a more severe case of post polio syndrome 
with a greater loss of muscle function and more severe fatigue and cramps1.  
 
 
1.1.4.3 Metabolic Disorders 
Around 30% of pregnant women suffer from cramps in the third trisemester of 
pregnancy. The cause is unknown, but it is assumed as secondary either to the metabolic 
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changes associated with pregnancy or to the fluid retention and joint laxity that 
accompany the later stages of pregnancy1. 
 
Endocrine disorders, such as hypoadrenalism, uraemia and hypothyroidism, can be 
associated with cramps. It has been reported that 20%-50% of hypothyroid patients 
complain of muscle pain or cramps13. Hypothyroid-associated muscle problems typically 
manifest as polymyositis-like with proximal muscle weakness, cramps and an increase 
in CK levels13. In patients suffering from uraemia, up to 50% of them experience muscle 
cramps, and seem to not have any secondary association with neuropathy that is caused 
by kidney disease1. 
 
Liver disease and cirrhosis are also associated with increased cramps, which may be due 
to decreased intravascular volume in cirrhosis patients.  The prevalence of muscle 
cramps among cirrhosis patients may vary, and was reported at around 22% to 88%1.  
 
Performing intense muscular work in a hot environment has been associated with heat 
cramps. Miners, stokers, cane-cutters, firemen and athletes are among those who are 
susceptible to this type of cramps. People suffering from heat cramps present evidence 
of hyponatraemia and volume depletion; thus, taking salt tablets during the work may 
prevent these cramps1, 5. 
 
 
1.1.4.4 Acute Extracellular Volume Depletion 
It is noted that around one third of patients undergoing haemodialysis complain of 
muscle cramps. Sodium profiling, a procedure conducted by varying the sodium content 
of the dialysis fluid during the dialysis session can be helpful in reducing the cramps 
incidence. Similar to heat cramps, any acute extracellular volume depletion may 
precipitate cramps, which may occur by having excessive perspiration, diarrhoea, 
diuretic therapy or vomiting1, 6.  
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1.1.4.5 Hereditary Disorders 
Several families have been described with autosomal-dominant inherited generalized 
muscle cramps. In these families, the cramping is often first recognized and most severe 
during adolescence1, 6.  
 
 
1.1.4.6 Medications 
A few medications are notable for causing muscle cramps, such as statins (cholesterol-
lowering medication), beta-adrenergic agonists, donezepil, neostigmine, raloxifene, 
nifedipine, terbutaline, salbutamol, and diuretics. Muscle cramps can also happen during 
withdrawal from sedative effect-substances, such as anxiolytics and barbiturates1, 6, 14. 
 
 
 
1.1.5 Treatment of Cramps 
 
1.1.5.1 Non-pharmacological treatment 
 
Lengthening or stretching the cramped muscle and activating the antagonist muscles are 
the most common, effective and non-pharmacological treatments for cramps1, 15. 
Stretching a cramped muscle may trigger temporary increased pain, but provides 
eventual relief5. Stretching can also be a preventive strategy, as a study with 44 patients 
having nocturnal leg cramps showed a reduction in cramp frequency after stretching 
their calf three times daily1.  
 
Adding sodium (50 mmol/L) to fluid replacement in order to prevent exercise-related 
fluid losses may be helpful as it can maximize fluid retention16. Typical sport drinks may 
not be very helpful as they only contain sodium levels of 10-25 mmol/L, and it has been 
proven these sport drinks only have slight benefit over water16. A combination of water 
and ingestion of food with salt content can perhaps be helpful in preventing exercise-
related cramps.17 
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1.1.5.2 Pharmacological Treatment 
According to Jansen et al18, quinine and its derivatives, hydroquinone and quinidine, 
have been used for more than 50 years to treat muscle cramps. Quinine is very effective 
in reducing cramps by increasing the muscle refractory period and decreasing the 
excitability of the motor endplate to nerve stimulation1, 19, 20.  Despite its effectiveness in 
treating cramps, quinine can cause toxicity, called cinchonism, which occurs with 
quinine levels of 5-10 mg/L. The symptoms include temporary visual and hearing 
disturbances, dizziness, fever, nausea, vomiting and diarrhea, blindness (can be 
permanent when the levels of quinine exceed 10 mg/L), and thrombocytopenia. From 
1969-1992, there have been 157 reports of adverse drug reactions related to quinine 
sulfate use in the US, including 23 that resulted in death1. Since 2004, NPS no longer 
recommends quinine for cramps treatments. 
 
Sodium channel-blocking agents, such as carbamazepine and phenytoin, can be used to 
treat muscle cramps even though their side effects are not favorable1, 6, 21. Table 1.4 
summarizes the examples of pharmacological therapies for muscle cramps and their side 
effects1, 21. 
 
Table 1.4 Pharmacological treatments for muscle cramps and their side effects1, 21 
Medication Typical dose Side effects 
Quinine sulfate 300 mg at 
bedtime 
Headache, hypoglycaemia, nausea or 
vomiting, dysphagia, rash, 
thrombocytopenia, disseminated 
intravascular coagulation, haemolytic-
uraemic syndrome, ototoxicity, 
hepatotoxicity, and interstitial nephritis 
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Table 1.4 Pharmacological treatments for muscle cramps and their side effects1, 21 
contd.. 
Carbamazepine 100 to 200 mg at 
bedtime 
Blurred vision, double vision, dizziness, 
clumsiness, hypertension, hypotension, 
nausea, vomiting, drowsiness, pruritic rash, 
bone marrow depression, thrombocytopenia, 
renal toxicity, hyponatraemia, 
hypocalcaemia, arrhythmias, AV heart 
block, congestive heart failure, syncope, 
hepatitis, Steven-Johnson syndrome. 
Phenytoin 100 to 200 mg at 
bedtime 
Ataxia, dizziness, encephalopathy, gingival  
hyperplasia confusion, osteomalacia, rash, 
leukopenia, pancytopenia, Steven-Johnson 
syndrome, thrombocytopenia, liver damage, 
toxic hepatitis. 
 
 
1.2 STATIN-INDUCED MYOPATHY AND MUSCLE CRAMPS 
 
1.2.1 Statins 
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
are cholesterol-lowering medications. A lead compound of statins, mevastatin, was 
extracted from Penicillium citrinum by Endo et al in 197122. The second type of statin, 
lovastatin, was extracted from Aspergillus terreus in 197822, 23.  
 
Other types of statins, such as simvastatin and pravastatin, are semi-synthetic. 
Simvastatin is derived from lovastatin by adding a methyl group on the carbon α to the 
carboxyl group, while pravastatin is a mevastatin analogue with a hydroxyl group on the 
decalin ring, which is prepared from mevastatin by microbial transformation using 
Streptomyces carbophilus. The next generation of statins, namely fluvastatin, 
cerivastatin, atorvastatin, and rosuvastatin, are completely synthetic statins with very 
different structures from the statins derived from fungal products22 (Figure 1.1). 
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Figure 1.1 Chemical Structures of HMG-CoA and Statins (Source: Endo A22) 
 
  
 
 
In Australia, there are four statins that are widely used, namely atorvastatin (Lipitor®), 
fluvastatin (Lescol®, Vastin®), pravastatin (Pravachol®) and simvastatin (Zocor®, 
Lipex®)21 (Table 1.5). Recently, rosuvastatin (Crestor®) has been released onto the 
market. 
 
Table 1.5 Statins distributed in Australia21 
Generic Name Patent Name® Dosage and Availability 
Atorvastatin Lipitor Tablet 10, 20, 40 and 80 mg 
Fluvastatin Lescol 
Vastin 
Capsule 20 and 40 mg 
Pravastatin Pravachol Tablet 10, 20 and 40 mg 
Simvastatin Lipex 
Zocor 
Tablet 5, 10, 20, 40 and 80 mg 
Rosuvastatin Crestor Tablet 5, 10, 20 and 40 mg 
 
 
 11
1.2.1.1 Chemistry and Functional Properties 
Among the statins, lovastatin and simvastatin have a lactone ring in their structure and 
are transformed into the active open acid form in the body while pravastatin is 
administrated as the biologically active open acid form. Other statins have an open acid 
form and have a similar structure to flurophenyl groups22, 23. The clinical importance of 
the structural variations between statins is that they determine their pharmacological 
effects and differing pharmacokinetic properties (Table 1.6)24.  It can be seen from Table 
1.6 (row 2) that atorvastatin and rosuvastatin are considered the most efficacious among 
all statins in lowering LDL cholesterol24. 
Table 1.6 Pharmacological and Pharmacokinetic Properties of Statins24 
 
Variable Atorvastatin Cerivastatin# Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin 
LDL 
cholesterol 
reductions  
(Dose range, 
mg) 
38%-54% 
 
 
 
(10-80) 
25%-44% 
 
 
 
(0.2-0.8) 
17%-33% 
 
 
 
(20-80) 
29-48% 
 
 
 
(20-80) 
19%-40% 
 
 
 
(10-40) 
52-63% 
 
 
 
(10-40) 
28-48% 
 
 
 
(10-80) 
IC50 purified 
human HMG 
CoA reductase 
 
8.2 
 
10.0 
 
27.6 
 
NA 
 
44.1 
 
5.4 
 
11.2 
Specify for 
hepatocytes + 
 
2.2 
 
-0.14 
 
-0.44 
 
NA 
 
3.3 
 
3.3 
 
0.54 
Elimination 
half-life 
(hours) 
 
15-30 
 
2.1-3.1 
 
0.5-2.3 
 
2.9 
 
1.3-2.8 
 
19 
 
2-3 
Bioavailability 
(%) 
 
12 
 
60 
 
19-29 
 
5 
 
18 
 
20 
 
5 
Protein 
Binding (%) 
 
80-90 
 
>99 
 
>99 
 
>95 
 
43-55 
 
88 
 
94-98 
Solubility * Lipophilic Lipophilic Lipophilic Lipophilic Hydrophilic Hydrophilic Lipophilic 
CP450 
metabolism 
and isozyme 
 
3A4 
 
3A4, 2C8 
 
2C9 
 
3A4 
 
- 
 
Limited 2C9 
 
3A4, 3A5 
 
# Withdrawn from the market worldwide 
+ Log ratio of IC50 in rat hepatocytes to IC50 in rat fibroblasts 
* Determined according to log D at PH 7.4 
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1.2.1.2 Cholesterol-Lowering Effect of Statins 
Statins inhibit the formation of mevalonate, a precursor of cholesterol produced by 
HMG-CoA reductase23, 25-31. Inhibition of this enzyme leads to a reduction in cholesterol 
levels (see Figure 1.2). A decline in serum cholesterol level leads to an up regulation of 
LDL-receptors by transcription regulation to maintain the intracellular cholesterol 
homeostasis. However, cytochrome P450 7A1 that is specific to the liver, transforms 
intracellular cholesterol to bile acids, resulting in a decline of cholesterol in hepatocytes, 
even though it is taken up via up regulated LDL-receptors. Biodegradation of cholesterol 
in the liver results in a decline of total cholesterol in the body23, 24, 26, 32-34.  
 
 
Figure 1.2 Reaction pathway of the biosynthesis of cholesterol, CoQ10 
(Ubiquinone) and dolichols (Source: Bliznakov35). 
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1.2.1.3 Other Pharmacological Effects of Statins 
In addition to the inhibition of cholesterol biosynthesis, statins also have other effects 
related to anti-atherosclerosis. Mevalonic acid, a substance whose synthesis is inhibited 
by statins, is a precursor of not only cholesterol, but also other metabolites, such as 
farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These substances mediate 
the prenyalation of specific proteins, which are involved in cell signal transduction, 
differentiation, proliferation, myelanation and cytoskeleton dynamics. Therefore, statins 
possess anti-atherosclerosis effects by modulating such cell function triggered by the 
inhibition of protein prenylation23, 36. Table 1.7 shows further details of the mechanisms 
of anti-atherosclerotic effects of statins23. 
 
Table 1.7 Mechanisms of anti-atherosclerotic effects of statins23 
No. Mechanisms of anti-atherosclerotic effects 
1. Inhibition of migration and proliferation of arterial myocytes 
2. Inhibition of macrophage growth 
3. Inhibition of cell adhesion 
4. Inhibition of superoxide generation 
5. Inhibition of cholesterol accumulation in macrophages 
6. Inhibition of tissue factor expression and activity 
7. Inhibition of endotherlin-1 synthesis and expression 
8. Induction of myocytes apoptosis in proliferative lesions 
 
 
 
1.2.2. Statin-Induced Myopathy 
Patients taking statins may suffer from a number of adverse effects, including muscle 
problems (myopathy)24, 37-47. In 2001, Baycol® (Cerivastatin) was withdrawn from the 
market after 31 cases of fatal rhabdomyolysis in the US and 52 deaths worldwide33, 35, 39, 
40.  
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The terminology to describe myopathy is not quite consistent. For example, myopathy 
has been defined as muscle pain, weakness or tenderness associated with abnormal 
elevations in CK levels (over 10 times the upper limit of normal), while the American 
College of Cardiology/American Heart Association/National Heart, Lung, and Blood 
Institute (ACC/AHA/NHLBI) refers to myopathy in general terms of muscle diseases24, 
39, 48.  
 
In 2006, The National Lipid Association’s (NLA) Muscle Safety Expert Panel was 
charged to assess statin safety and re-examine the definition used to define myopathy, 
particularly statin-induced myopathy49. The panel suggested that myopathy is the 
general term for all of the following muscle problems: 
 
1. Symptomatic myopathy: this term refers to skeletal muscle complaints, including 
myalgia, muscle weakness, and muscle cramps. 
2. Asymptomatic myopathy: this term refers to CK elevations without symptoms or 
objective evidence of weakness. 
3. Clinically important rhabdomyolysis: this term refers to any evidence of muscle 
leakage, regardless of the CK levels, and is considered to be causally related to a 
change in renal function.  
 
The panel also suggested that the term rhabdomyolysis may be replaced by classes of 
absolute CK elevations, including: 
 
a. Mild CK increase: this term refers to CK levels greater than normal, but less than 10 
times of ULN. 
b. Moderate CK increase: this term refers to CK levels more than 10 times the ULN but 
less than 50 times the ULN. 
c. Marked CK increase: this term refers to CK levels over 50 times the ULN. 
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1.2.3 Statin-Induced Muscle Cramps 
As part of statin-induced myopathy, unfortunately there is very little literature dealing 
specifically with statins-induced muscle cramps, since most of the statin-induced muscle 
disorders study are focused more on other types of statin-induced muscle disorders, 
namely myalgia, myositis and rhabdomyolysis. Sinzinger et al50, in their review, stated 
that there was a 25% increase in the probability of suffering from cramp and ache-like 
symptoms and muscle weakness for patients doing exercise and treated with statins. 
Another muscle cramp related review by Ucar et al46 point out that, in a trial with 10 to 
20 mg per day of simvastatin, from 2085 patients, 41 patients suffered from myalgia, 7 
patients suffered from muscle weakness, 6 patients suffered from muscle cramps, while 
arthralgia and gout were suffered by 4 and 1 patients respectively.  
 
Even though muscle cramps only accounted for a small number of total muscle 
disorders, Thompson et al37stated that less serious adverse effects of statin (including 
muscle cramps) are underreported, and may vary between 1% and 5%. Furthermore, 
since muscle cramp, particularly nocturnal leg cramp, is commonly experienced by 
about 35-60% of older people, some of whom may take statins, they may not realize that 
their muscle cramps may be caused by or worsened by statins. This statement is 
strengthened by Gaist et al51 who believed people taking statins are 7.6-fold more likely 
to suffer from myopathy, including muscle cramps, than people not taking statins. 
 
 
 
1.2.4 Pathophysiology of Statin-Induced Muscle Cramps 
As statin-induced muscle cramps are classified as one of the statin-induced 
myopathies48, their pathophysiology has the same basis as other statin associated muscle 
problems. The most widely supported mechanism for statin-induced myopathies is 
statin-induced lowering of CoQ10 levels35, 38, 42, 48, 52-56.  
 
Human57 showed that there was a decline in CoQ10 as well as vitamin E blood levels 
amongst hypercholesterolaemia patients after 14 weeks treatment with 10 and 20 mg per 
day of simvastatin.  Colquhoun58 reported  simvastatin 20 mg per day reduced CoQ10 
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and vitamin E blood levels after 6 months treatment. Other researchers, Rundek54, 
Strey59 and Mabuchi60, reported that atorvastatin also reduced CoQ10 blood levels. 
Another study conducted by Mortensen revealed that there was a reduction in CoQ10 
serum levels in patients taking pravastatin and lovastatin61. It was also reported that 
CoQ10 muscle levels were below 50% of control values in a patient who had been 
treated first with simvastatin (2 years) and then atorvastatin (2 years)62.  
 
As CoQ10 and cholesterol have the same biochemical pathway (Figure 1.2), the 
inhibition of HMG-CoA reductase by statins does not only reduce cholesterol levels but 
also CoQ10 blood levels38, 42, 48, 63. Furthermore, since CoQ10 is carried in the 
circulation by serum lipoproteins, the reduction of cholesterol and triglyecerides by 
statins also contributes to further reduced CoQ10 blood levels55, 64, 65. Beside being an 
important antioxidant, CoQ10 also functions as a transmembrane proton conductor and 
an electron carrier between NADH and succinate dehydrogenases and the cytochrome 
system, which is needed for phosphorylation of ADP into ATP66-71. As muscles need 
ATP to meet energy demands, a decline in the CoQ10 tissue may contribute to muscle 
impairment35, 38, 42, 48, 52-56.  
 
 
 
 
1.3 COENZYME Q10  
 
1.3.1 Biosynthesis of Coenzyme Q10 
Coenzyme Q10 (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone), also known 
as ubiquinone, is a naturally occurring and extremely hydrophobic molecule, with 
characteristics common to vitamins. This substance is called CoQ10 as this compound 
has 10 isoprenoid units in the side chain. CoQ10 is widely found in living organisms, 
including yeast, plants, animals and humans. CoQ10 plays a critical role as an 
antioxidant and electron transfer in the mitochondrial inner membrane involved in the 
efficient production of high-energy phosphates necessary for muscle contraction and 
other cellular function42, 67, 71-74.  
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Crane et al discovered CoQ10 in 1957 as a component of beef heart mitochondria. In 
1958, Folkers et al successfully determined the chemical structure of CoQ1068 (see 
figure 1.3). The content of CoQ10 in organs decreases with age, and its content vary 
between human tissues, with heart, liver, kidneys, muscle, pancreas and thyroid gland 
containing 114 μg/g, 66.5 μg/g, 55 μg/g, 40 μg/g, 33 μg/g, 24.7 μg/g tissue 
respectively66, 72, 75, 76. 
 
 
Figure 1.3 Chemical Structures of Ubiquinone-10 and Ubiquinol-10 (Source: 
Bliznakov35) 
 
 
 
  
 
 
CoQ10 is synthesized in all cells from mevalonate and tyrosine, and requires the 
availability of multiple vitamins in their coenzyme forms, such as vitamin B2, B6, B12, 
C, folic acid, niacinamide, pantothenic acid and other trace elements35. Figure 1.4 shows 
further details of CoQ10 biosynthesis in the human body.  
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Figure 1.4 The Biosynthesis of Coenzyme Q10 (Source: Chan et al71) 
 
  
 
The biosynthesis of CoQ10 can be reduced by statins, due to the fact that they inhibit the 
formation of mevalonate. Furthermore, a reduction in CoQ10 blood levels of statin users 
could also be related to the fact that statins lower plasma LDL-C level, and CoQ10 is 
mainly transported by LDL-C. Although CoQ10 can be obtained from foods, such as 
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meat and fish, its content in them is very low. Therefore, some nutritionists have 
considered the use of CoQ10 as a dietary supplement35, 55, 66, 70, 75.     
 
1.3.2 The Role of Coenzyme Q10 in the Respiratory Chain 
CoQ10 plays a crucial role in the mitochondrial respiratory chain, distributing the 
electrons between the various dehydrogenases and the cytochrome segments of the 
respiratory chain (Figure 1.572).  
 
Figure 1.5 The Central Role of CoQ10 (Q) in the Respiratory Chain (Source: 
Rustin et al72). Thick lines symbolize electron flow through the respiratory chain. 
Dotted lines correspond to electron exchanges between kinetically compartmentalized 
CoQ10 pools. Thin lines represent the antioxidant activity of CoQ10. 
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A CoQ10 cycle at the respiratory chain complex III allows protons to be extruded from 
the mitochondrial matrix to the inter membrane space along with electrons flowing 
through the complex.  Furthermore, depending on its redox and protonation status, 
CoQ10 can react with molecular oxygen to produce superoxides. Besides the pro-
oxidant effect of CoQ10, the fully reduced form of CoQ10, ubiquinol, can reduce a 
number of radical species, such as superoxides, hence acting as an antioxidant. 
Therefore, CoQ10 can act as both a pro- and an antioxidant molecule71, 72. 
 
CoQ10 is a very crucial antioxidant and playing a pivotal role in the mitochondrial 
respiratory chain, distributing the electrons between the various dehydrogenases and the 
cytochrome segments of respiratory chain. A decline in CoQ10 levels may result in an 
increase of NADH/NAD ratio, a decrease in mitochondrial ATP formation, an increase 
of superoxide formation, and the functional impairment of numeric metabolic pathways 
requiring the respiratory chain function. Furthermore, since quinone-dependent 
oxidative phosphorylation supplies most organs and tissues (such as muscle) with 
energy, CoQ10 depletion should theoretically result in various clinical manifestations71, 
72. 
 
 
 
1.3.3 The Role of Coenzyme Q10 as an Antioxidant 
The reduced form of CoQ10, ubiquinol, mediates the antioxidant role of endogenous 
CoQ10, which is able to prevent lipid peroxidation-mediated protein damage (Figure 
1.671). Ubiquinol can be formed from the activity of mitochondrial Complex I (NADH 
dependent ubiquinone oxireductase), Complex II (succinate dependent FADH or 
ubiquinone oxireductase), NAD(P)H dependent quinone oxidoreductase (NQO1), and 
NADPH dependent ubiquinone reductase (UQR)35, 55, 71, 75.   
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Figure 1.6 The Antioxidant Activity of Ubiquinol (Source: Chan et al71). (A) NADH 
dependent regeneration of ascorbate from ascorbyl radical. (B) NAD(P)H dependent 
regeneration of tocopherol from its chromanoxyl radical. (C) Scavenging of lipid 
peroxyl and carbon-centered radicals in a direct lipid peroxidation chain-breaking role. 
 
  
  
As can be seen from Figure 1.6 above, ubiquinol is also able to supplement other 
antioxidants, such as vitamin E (α-tocopherol) and C (ascorbate). Ubiquinol can mediate 
the regeneration of α-tocopherol from its chromanoxyl radical. However, another form 
of CoQ10, called ubisemiquinone, is noted to be able to auto-oxidize to form 
superoxide, if allowed access to H2O. This pro-oxidant activity may only be significant 
if cellular antioxidant mechanisms are severely compromised71.  
 
Another antioxidant, ascorbate, is regenerated across the plasma membrane with the aid 
of ubiquinol, cytochrome b5 reductase, and a heme containing enzyme responsible for 
mediating the transfer of electrons from intracellular NADH to extracellular electron 
acceptors such as the ferrycyanide and ascorbyl radical71. 
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1.3.4 The Safety of Coenzyme Q10 
Ikematsu et al75 conducted a double-blind, randomized, placebo-controlled study in 
order to assess the safety of CoQ10 in a total of  88 healthy subjects. In this 4-week 
study, participants were given CoQ10 at doses of 300, 600, and 900 mg per day. It was 
reported that there were no serious adverse events observed in any group. The most 
common adverse effects were common colds and flu symptoms and gastrointestinal 
problems (such as abdominal pain and soft faeces).  
 
Hatchcock and Shao77 carried out another risk assessment. After examining 54 studies 
associated with CoQ10 clinical trials, they reported that the adverse effects of CoQ10 
are mild, such as nausea, and upset stomach. Reports of nausea and other gastrointestinal 
effects of CoQ10 cannot be causally related to the active ingredient because there is no 
dose-response relationship. The absence of a dose relationship between CoQ10 and 
nausea suggests that the capsule or oil vehicle, and not CoQ10 itself, may have been 
responsible for the nausea effect. 
 
Other possible adverse effects of CoQ10 are reported by Weiss78. Weiss states that 
besides nausea, vomiting and upset stomach, people taking CoQ10 may also experience 
heartburn, diarrhoea, loss of appetite, skin itching, rash, insomnia, headache, dizziness, 
fatigue or flu-like symptoms. These side effects will stop without requiring any 
treatment78, 79. CoQ10 may also lower blood sugar and blood pressure levels, and reduce 
the effectiveness of warfarin80, 81. Furthermore, there is not enough information about the 
safety of CoQ10 amongst pregnant and breastfeeding women80, 81. 
 
In terms of the safety of CoQ10 in statin users, it is reported that CoQ10 therapy 
prevents a reduction in both platelet and plasma CoQ10 levels without affecting the 
cholesterol lowering effect of the statin55, 56. Authors of a small number of studies35, 58, 60 
together with associations such as the International Coenzyme Q10 Association to the 
United State Food and Drug Administration82, and the International College of 
Cardiology 82, have recommended the use of CoQ10 for statin users.  
 
 23
CoQ10 efficacy has been examined by Caso et al83 who assessed the effectiveness of 
CoQ10 and vitamin E in reducing muscle pain (myalgia) associated with statin 
treatment. It was revealed that after a 30-day intervention, pain severity decreased by 
40%, and pain interference with daily activities decreased by 38% in the group treated 
with CoQ10. On the other hand, there were no changes in pain severity and pain 
interference with daily activity in the group treated with vitamin E.  
 
In 2002, Whitaker84 filled a citizen petition to the FDA to change the labeling for all 
statin drugs and insisted that all labels of  statin products should contain the 
recommendation for statin users to take 100 mg to 200 mg per day of CoQ10. To 
support his petition, Whitaker84 noted that Merck, the manufacturer of Mevacor® 
(lovastatin) and Zocor® (Simvastatin), holds two patents that cover doses containing up 
to 80 mg of an HMG CoA reductase inhibitor with 25 mg to 1 g of CoQ10. One patent 
(No. 4,933,165)85 specifically mentions that the combination of statins with CoQ10 will 
be effective in reducing adverse effects of statins.  
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CHAPTER TWO 
OBJECTIVES OF THE STUDY 
 
 
The objective of the study were as follows: 
 
1. To determine the frequency and nature of muscle symptoms among statin users 
in Western Australia. 
 
2. To assess factors that may influence the development of statin-induced muscle 
symptoms, including the dose and the duration of statin medication, age and sex 
of patients, history of muscle cramps, other medicines consumed concomitantly 
with statins, and other diseases suffered. 
 
3. To investigate the efficacy of CoQ10 in reducing muscle cramps amongst statin 
users and non-users. 
 
4. To document any adverse reactions associated with the use of CoQ10. 
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CHAPTER THREE 
METHODOLOGY 
 
3.1 ETHICS 
Ethics approval for the study was obtained from the Curtin University of Technology 
Human Research Ethics Committee (Appendices A and B). Patient Information Sheet 
and Informed Written Consent forms were developed in accordance with the 
requirements of the Curtin University of Technology Ethics Committee (Appendices C 
and D).   
 
3.2 DATA COLLECTION AND ANALYSIS 
The study was comprised of two phases: Phase 1 the “Muscle Adverse Effects Survey” 
and Phase 2 the “Coenzyme Q10 for Muscle Cramps Study”. 
 
3.2.1 Muscle Adverse Effects Survey 
3.2.1.1 Setting 
Data collection for this survey took place from January 2006 to April 2006 in 45 
community pharmacies throughout Western Australia (metropolitan 32, rural 13). 
 
3.2.1.2 Study Design 
This was an observational study adopting a prospective approach. 
 
3.2.1.3 Recruitment 
In this study patients were enrolled at the time of presenting a repeat prescription for a 
statin. Each patient was asked to complete a standardized questionnaire, either at the 
time in the pharmacy or at home, and return it to the Investigator using a prepaid 
envelope provided. 
 
3.2.1.4 Questionnaire Design 
The questionnaire was adopted from a myopathy survey of IMPOSTER (“Is Myopathy 
Part of Statin Therapy?”) Study86. The following data were recorded: the respondent’s 
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age and sex; the dose and duration of their statin therapy; muscle symptoms (nature, 
duration and whether or not they have changed with statin use); other medicines 
consumed; and other diseases suffered. 
 
3.2.1.5 Definition of Terms 
For the purpose of this survey, the following definitions were used: 
 
1. Diabetes mellitus is defined as a disorder that results from insulin hyposecretion 
and/or insulin insensitivity, and is associated with hyperglycemia87.   
2. Hypertension is defined as a condition notified by an increase in blood pressure to an 
extent where clinical benefit is obtained from blood pressure lowering88. 
3. Heart attack (ischaemia heart disease) is defined as a condition where the vascular 
supply to the heart is obstructed by thrombosis, atheroma or spasm of coronary 
arteries, which may impair the supply of oxygenated blood to cardiac tissue89. 
4. Heart failure is defined as a condition where the heart fails to sustain an adequate 
delivery of blood, with symptoms including fatigue, and shortness of breath90. 
5. Hypothyroidism is defined as a condition that mostly results from reduced 
production of thyroid hormones, which can cause weakness, lethargy, cold 
intolerance, slowness, memory loss, and weight gain91.   
6. Acute renal failure is defined as a condition signified by a decline in the excretory 
function of the kidneys over a period of days or weeks leading to an accumulation of 
nitrogenous waste products and other toxins92.   
    
 
3.2.1.6 Sample Size 
Based on estimates of myopathy rates of 1-5% amongst statin users37, a minimum of 700 
participants were needed for the “Muscle Adverse Effects Survey” to identify 35 
potential participants for Group A in phase 2 of the study (“Coenzyme Q10 for Muscle 
Cramps Study”). 
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3.2.1.7 Data Analysis 
Window based Statistical Package of the Social Sciences (SPSS) Version 13 was used to 
perform the following statistical analyses: the Pearson chi square statistical test, 
independent-t test, and logistic regression test.  
 
The data obtained from the questionnaires were numerically coded and entered into an 
SPSS package. All coding and data entry were checked upon completion in comparison 
with original questionnaires. A P-value less than 0.05 was considered statistically 
significant.   
 
 
3.2.2 Coenzyme Q10 for Muscle Cramps Study 
3.2.2.1 Setting 
This clinical trial took place through the School of Pharmacy, Curtin University of 
Technology, from May 2006 to December 2006. 
 
3.2.2.2 Study Design 
This study had a single blind, placebo-controlled, cross over design. 
 
3.2.2.3 Advertisement for the trial 
This study was advertised at 45 community pharmacies in WA, and through Curtin 
University’s Radio station, and in two Western Australia community newspapers. 
 
3.2.2.4 Recruitment 
For patients to be eligible for the study they had to fulfill the following criteria: 
 
1. Suffered from muscle cramps at least once a week 
2. Be aged over 18 years 
3. Be able to consent to participate in the study 
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Patients were excluded from the study if they: 
1. Were pregnant or breastfeeding 
2. Had cognitive impairment and /or language barrier 
3. Had unfavourable health condition(s) as advised by their general practitioner, 
such as severe hypertension, severe hypotension, renal failure, and uncontrolled 
diabetes mellitus 
4. Had been taking CoQ10 
5. Were taking warfarin.  
 
Patients who were interested in joining this study were given the Participant Information 
Sheet, and asked to sign the Consent Form. They were required to come to the research 
centre at the School of Pharmacy, Curtin University of Technology, to meet the 
Investigator.  The Investigator explained further details of the study design and answered 
any questions that they might have at that time. As taking part in this study was 
voluntary, participants were free to choose not to take part or may leave the study at any 
time without penalty. Participants were separated into two groups; Group A was those 
suffering from muscle cramps who were taking statins, and Group B (Controls) was 
those suffering from muscle cramps but not taking statins.   
 
3.2.1.5 Clinical Trial Protocol 
The trial consisted of four phases: Phase 1 - a 1-week assessment period, during which 
the baseline frequency of muscle cramps was assessed; Phase 2 - a 2-week treatment 
period, during which participants of Group A were allocated CoQ10 100 mg/day, and 
Group B were allocated placebo; Phase 3 - a 1-week wash out period during which 
participants did not take either CoQ10 or placebo; and Phase 4 -  a second 2-week period 
of the second treatment during which participants of Group A took placebo, and Group 
B took CoQ10 100 mg per day.  
 
The CoQ10 capsules used in this study were manufactured by Blackmore Ltd, and each 
capsule contained CoQ10 50 mg. The placebo capsules contained extra virgin olive oil, 
and were manufactured by the School of Pharmacy, Curtin University of Technology. 
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As it was not possible to have identical placebo capsules to the commercial Blackmores’ 
CoQ10, the study had to be a single blind study.  
 
During the treatment periods (Weeks 2, 3, 5 and 6), participants were advised to take the 
medication (either CoQ10 or placebo), two capsules daily with the evening meal. 
Patients were then given a diary to record the following data across the 6-week period of 
the study: 
 
1. Days on which cramps were experienced 
2. Number of cramps suffered per day 
3. Average pain score associated with muscle cramps (on a scale of 0 to 10) 
4. Maximum pain score associated with muscle cramps (on a scale of 0 to 10) 
5. The duration of the cramps (in minutes)   
6. The part(s) of the body affected by the cramps 
7.  Any adverse reactions suffered over the duration of the study 
 
During the study, the Investigator monitored the condition of participants by 
interviewing them once a week (by face-to-face meetings or by telephone interviews).  
At the end of the study, their diaries were collected by the Investigator, and participants 
were given the opportunity to receive a copy of the results of the study. 
 
 
3.2.1.6 Definition of Terms 
For the purpose of this study, the following definitions were used: 
1. “Average pain score” was defined as the average score of pain intensity associated 
with the muscle cramps, which is determined by using the pain severity scale (Figure 
3.1). 
 
 
 
 
 30
     Figure 3.1 Numeric Rating Scale 
 
 
 
The pain severity scale used in this study has been adopted from the numeric rating 
scale (NRS) of the Office of Academic Affiliations, US Department of Veteran 
Affairs 93. On the NRS, 0 is marked as no muscle pain associated with the muscle 
cramps, while 10 means the worst possible pain of muscle cramp.  
 
The numeric rating scale (NRS) adopted in this study has already been proven valid 
and reliable94-96. A study conducted by Ferraz et al95 found that NRS had higher 
reliability in both literate and illiterate patients compared to other scales, namely the 
visual analogue scale (VAS) and the verbal rating scale (VRS).   
 
2. “Maximum pain score” was defined as the maximum score of pain intensity 
associated with the muscle cramps, which is determined by using the pain severity 
scale (Figure 3.1). 
 
3. “Duration of the cramps” was defined as the length of the cramp episode that may 
last for a few seconds or up to 10 minutes. The limitation for the contraction of 
muscle cramps up to 10 minutes is used in order to distinguish muscle cramp from 
painful muscle stiffness18. The duration of the cramps was determined by using 
either a wristwatch or a stopwatch. 
 
4. “Adverse effects” were defined as unfavourable medical events, including subjective 
symptoms and objective symptoms, that participants commented on after taking the 
medication, regardless of whether they appeared related to the test material75. 
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3.2.1.7 Sample Size 
A total number of 70 patients were expected to be recruited for this trial. This sample 
size is based on previous research on muscle cramps using hydroquinone, which was 
conducted by Jansen et al18.  
 
3.2.1.8 Data Analysis 
Window based Statistical Package of the Social Sciences (SPSS) Version 13 was used to 
perform the following statistical analyses: repeated measures ANOVA, Scheffè test, and 
paired t-test.   
 
The data obtained from the diary were numerically coded and entered into an SPSS 
package. All coding and data entry were checked upon completion in comparison with 
original diaries. A P-value less than 0.05 was considered statistically significant.   
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CHAPTER FOUR 
RESULTS 
 
 
4.1. MUSCLE ADVERSE EFFECTS SURVEY  
4.1.1 Recruitment   
Participants for the study were recruited through 45 community pharmacies in Western 
Australia (metropolitan 32, rural 13). Participants enrolled into the study were asked to 
complete a questionnaire, which was adopted from a myopathy survey of IMPOSTER 
(“Is Myopathy Part Of Statin Therapy?”)86, either at the time in the pharmacy or at home 
and return it by post. Of the 920 participants enrolled into the study who took the 
questionnaire, 356 (38.7%) returned the questionnaire. 
 
4.1.2 Patient Demographics 
The 356 respondents were made up of 202 males and 156 females. The average age of 
male respondents was 60.5 ± 11.1 (SD) years and the average age of female respondents 
was 64.1 ± 11.3 (SD) years. Two hundred and five of the 356 (57.6%) respondents, 111 
men and 94 women, reported muscle symptoms (Table 4.1).  T testing for the equality of 
the mean was undertaken, and the results demonstrated that respondents suffering from 
muscle symptoms were significantly older than those who did not experience any 
muscle symptoms (Mean difference 4.89 years; 95% CI: 2.65 – 7.31, p value= 0.000) 
[Table 4.1]. 
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Table 4.1 the Age and Gender of Participants 
 
For the purpose of analysis it was assumed that non-respondents did not suffer from 
muscle symptoms, which reduced the overall incidence to 205/920 or 22.3%. Amongst 
the respondents with muscle symptoms, 73 (35.6%) reported their muscle symptoms had 
worsened on using their statins, 42 (20.6%) admitted they experienced darkening of their 
urine after exercise or fasting, and 26 (12.7%) admitted they had a family history of 
muscle disorders.   
Furthermore, amongst the respondents with muscle symptoms, 98 respondents (49.8%) 
had liver function tests done, and 44 (21.5%) and 10 (4.9%) had CK and myoglobinuria 
tests done respectively.  However, there’s no further information obtained regarding 
these tests, as their test results were not attached to the questionnaire.    
 
4.1.3 Lipid Lowering Therapy Used 
The survey found that atorvastatin was the most commonly prescribed statin (59.3%), 
followed by simvastatin (29.8%) and then pravastatin (10.4%) and fluvastatin (0.6%). 
As can be seen from the Table 4.2 below, despite the high use of atorvastatin, the 
incidence rate of myopathy amongst individual atorvastatin users was found to be 
similar to that of other statins.  
 
Group Number Males Females Mean of Age 
(95% CI) 
SD p value
(Mean 
of Age)
Myopathy 205 
 
111 94 64.2 (62.7-65.7) 10.8 
Non 
myopathy 
151 
 
91 60 59.2 (57.4-61.0) 11.4 
0.000 
 34
Table 4.2 Statin Therapy Used   
  
From a total of 356 participants, seven (1.9%) took a combination of statins with other 
cholesterol lowering medications, namely gemfibrozil, ezetimibe, and fenofibrate. Table 
4.3 summarizes the type of statins (including their combination), and their doses used by 
respondents. It can be seen from the table that the incidence rates for myopathy and non-
myopathy amongst statin doses remained statistically indistinguishable (p>0.05).  
 
Table 4.3 Complete Lists of Statin Therapy Used 
Group  
Statin Used Myopathy 
n (%) 
Non-Myopathy 
n (%) 
 
Number of 
Respondents 
Proportion 
of 
Respondents 
(%) 
Atorvastatin 10 mg 56 (27.3%) 34 (22.5%) 90 25.3 
Atorvastatin 10 mg + 
Gemfibrozil 600 mg 
1 (0.5%) 1 (0.7%) 2 0.6 
Atorvastatin 20 mg 26 (12.7%) 24 (15.9%) 50 14.0 
Atorvastatin 40 mg 20 (9.8%) 21 (13.9%) 41 11.5 
Atorvastatin 40 mg + 
Fenofibrate 160 mg 
1 (0.5%) 0 (0%) 1 0.3 
Atorvastatin 60 mg (40 
mg + 20 mg) 
2 (0.9%) 0 (0%) 2 0.6 
Atorvastatin 80 mg 14 (6.8%) 10 (6.6%) 24 6.7 
Atorvastatin 80 mg + 
Ezetimibe 10 mg 
1 (0.5%) 0 (0%) 1 0.3 
Group  
Statin Used Myopathy 
N (%) 
Non-Myopathy  
N (%) 
 
Total Number of 
Respondents 
 
Proportion of 
Total 
Respondents 
(%) 
Atorvastatin 121(59.0%) 90 (59.6%) 211 59.3 
Fluvastatin 2 (0.98%) 0 (0%) 2 0.6 
Pravastatin 26 (12.7%) 11 (7.3%) 37 10.4 
Simvastatin 56 (27.3%) 50 (33.1%) 106 29.8 
Total responses 205 (100%) 151 (100%) 356 100 
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Table 4.3 Complete Lists of Statin Therapy Used Contd… 
Fluvastatin 20 mg 2 (0.9%) 0 (0%) 2 0.6 
Pravastatin 10 mg 13 (6.3%) 4 (2.6%) 17 4.8 
Pravastatin 20 mg 3 (1.5%) 7 (4.6%) 10 2.8 
Pravastatin 40 mg 9 (4.4%) 0 (0%) 9 2.5 
Pravastatin 80 mg 1 (0.5%) 0 (0%) 1 0.3 
Simvastatin 5 mg 12 (5.9%) 8 (5.3%) 20 5.6 
Simvastatin 10 mg 14 (6.8%) 12 (7.9%) 44 12.4 
Simvastatin 20 mg 8 (3.9%) 19 (12.6%) 27 7.6 
Simvastatin 20 mg + 
Ezetimibe 10 mg 
1 (0.5%) 0 (0%) 1 0.3 
Simvastatin 40 mg 13 (6.3%) 7 (4.6%) 20 5.6 
Simvastatin 40 mg + 
ezetimibe 10 mg 
0 (0%) 1 (0.7%) 1 0.3 
Simvastatin 80 mg 7 (3.4%) 2 (1.3%) 9 2.5 
Simvastatin 80 mg + 
Fenofibrate 160 mg 
0 (0%) 1 (0.7%) 1 0.3 
Total Responses 205 (100%) 151 (100%) 356 100 
 
 
In terms of the duration of medication use, the majority of participants in both the 
myopathy and non-myopathy groups had been taking a statin for over 1 year (301; 
84.6%) [Table 4.4]. 
 
Table 4.4 the Duration of Statin Used 
 
Group  
Duration of statin 
taken by participants Myopathy n (%)  
Non-
Myopathy   
n (%) 
 
Number of 
Respondents 
 
Proportion of 
Respondents 
(%) 
Less than 1 year 33 (16.1%) 22 (14.6%) 55 15.4 
More than 1 year 172 (83.9%) 129 (85.4%) 301 84.6 
Total responses 205(100%) 151 (100%) 356 100 
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4.1.4 Other Suffered Diseases besides Hypercholesterolemia 
It was found that besides hypercholesterolaemia, there were 301 cases of other diseases 
suffered by participants that might be associated to myopathy. The most commonly 
reported concomitant diseases were hypertension (n =140 cases or 39.3% cases of total 
respondents), followed by diabetes mellitus with 65 cases (18.3%), ischaemic heart 
disease with 41 cases (11.5%) and hypothyroidism with 36 cases (10.1%) [Table 4.5]. 
 
Table 4.5 Other diseases suffered besides hypercholesterolaemia 
Diseases  Myopathy 
n = 205 
Non-myopathy 
n = 151 
Number of 
Respondents  
Proportion of 
Respondents (%) 
Diabetes Mellitus 44 21 65 18.3 
Hypertension 84 56 140 39.3 
Ischaemia Heart 
Disease 
 
27 
 
14 
 
41 
 
11.5 
Heart Failure 13 1 14 3.9 
Hypothyroidism 23 13 36 10.1 
Kidney Failure 4 1 5 1.4 
No Diseases 74 67 141 39.6 
Total Responses 269 163 432 124# 
# Total exceeded more than 100% as many patients suffered from more than 1 concomitant disease 
 
4.1.5. Other Drugs Used Besides Statin 
Amongst the 356 respondents, 220 (61.8%) took other drugs that might be associated 
with myopathy while they were on statin therapy. It was found that alcohol (more than 2 
drinks daily) was the most commonly consumed drug (95 cases; 26.7% of total 
respondents), followed by vitamin E (47 cases; 13.2% total respondents), thyroxine (36 
cases; 10.1% of total respondents), vitamin D (33 cases; 9.3% of total respondents) and 
cortisone (23 cases; 6.5% of total respondents) [Table 4.6]. 
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Table 4.6 Other Drugs Used Besides Statin 
Drugs  Myopathy 
(n = 205) 
N (%) 
Non-Myopathy 
(n = 151) 
N (%) 
Number of 
Respondents 
Proportion of 
Total 
Respondents (%) 
Diltiazem 5  (2.5%) 3 (1.9%) 8 2.2 
Nifedipine 6 (2.9%) 1(0.7%) 7 1.9 
Verapamil 2 (1%) 1(0.7%) 3 0.8 
Alcohol (more than 
2 drinks daily) 
51 (24.9%) 44 (29.1%) 95 26.7 
Amiodarone 1 (0.5%) 0 (0%) 1 0.3 
Antimalarial 12 (5.9%) 1 (0.7%) 13 3.7 
Chemotherapy 6 (2.9%) 0 (0%) 6 1.7 
Colchicine 6 2.9%() 0 (0%) 6 1.7 
Cyclosporin 1 (0.5%) 0 (0%) 1 0.3 
Cortisone 21 (10.2%) 2 (1.3%) 23 6.5 
Labetalol 1 (0.5%) 0 (0%) 1 0.3 
Prednisone 16 (7.8%) 3 (2%) 19 5.3 
Thyroxine 23 (11.2%) 13 (8.6%) 36 10.1 
Sodium valproate 2 (1%) 1 (0.7%) 3 0.8 
Vitamin D 20 (9.8%) 13 (8.6%) 33 9.3 
Vitamin E 27 (13.2%) 20 (13.2%) 47 13.2 
Warfarin 16 (7.8%) 5 (3.3%) 21 5.9 
Other drugs 11 (5.4%) 6 (4%) 17 5.1 
None 66 (32.2%) 70 (4.6%) 136 38.2 
Total Responses 293 
(142.9%) 
183  
(121.2%) 
476 132 
 
 
 
 
4.1.6 Statin-Induced Myopathy 
On average, respondents in the myopathy group reported around 2.5 muscle symptoms, 
with the most commonly experienced being night cramps (54.6%), followed by muscle 
aching (52.7%), and fatigue/tiredness (49.3%) [Table 4.7]. 
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Table 4.7 Muscle Symptoms Suffered in the Myopathy Group 
Muscle symptoms Respondents with 
myopathy 
n = 205 
Proportion of 
Respondents* (%)  
Cramp at night 112 54.6 
Cramp after exercise 40 19.5 
Muscle aching/soreness 108 52.7 
Fatigue/tiredness 101 49.3 
Muscle weakness 66 32.2 
Breathlessness with exercise 55 26.8 
Other muscle symptoms 28 13.7 
Total cases 510 248.8* 
* Note many participants had multiple symptoms 
It was found that the majority of respondents suffering from muscle symptoms reported 
their calves as the most affected area of the body, accounting for 62%; while hips were 
reported as the least affected area of the body, affected in only for 0.5% of respondents 
(Table 4.8).  
 
Table 4.8 Part of the Body Experiencing Muscle Symptoms 
 Part of the body 
 
 Number of Respondents  Proportion of Respondents# 
(%) 
Calves 127 62.0% 
Thighs and buttocks 60 29.3% 
Back 40 19.5% 
Arms 34 16.6% 
Hands/fingers 6 2.9% 
Neck 9 4.4% 
Feet/toes 17 8.3% 
Ankles 6 2.9% 
Knees 4 2.0% 
Shoulders 7 3.4% 
Legs 3 1.5% 
Chest/ribs 3 1.5% 
Hips 1 0.5% 
All muscle hurt equally 11 5.4% 
No specific part 9 4.4% 
Other part of the body 2 1.0% 
Total cases 339 165.4%# 
# Total exceeded more than 100% as many patients suffered muscle cramps in more that one site in 
the body 
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The responses revealed that the majority of people in the myopathy group had been 
suffering from muscle symptoms for a period of 1 to 5 years (Figure 4.1). The symptoms 
were reported to most likely come and go throughout the day, but least likely to appear 
after exercise or on awaking (Table 4.9). 
 
Figure 4.1 Duration of myopathy suffered 
4.40%
26.30%
40.50%
23.40%
5.40% Less than 1 month
1-12 month
1-5 years
More than 5 years
No answer
 
 
Table 4.9 Frequency of Muscle Symptoms Suffered 
Frequency Number of Respondents Proprotion of 
Respondents (%) 
Constant throughout the day 26 12.7 
Comes and goes throughout the day 79 38.5 
Appears particularly at night 50 24.4 
Appears particularly after exercise 5 2.4 
Appears particularly while wake up 5 2.4 
Appears particularly in the morning 10 4.9 
Irregular 22 10.7 
No answer 8 3.9 
Total 205 100% 
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4.1.7 Factors Increasing the Risks of Statin-Induced Myopathy  
Logistic regression was performed modeling the dependent variables (myopathy) with a 
series of explanatory variables including: 
1. Patient age 
2. Gender of participants 
3. Statin therapy (Atorvastatin, Pravastatin and Simvastatin. Fluvastatin data were 
excluded from analysis due to low number of users) 
4. Duration of statin therapy 
5. Other diseases suffered (heart failure, ischemia heart disease, hypertension, 
hypothyroidism, diabetes mellitus and kidney failure) 
6. Other medicines taken (cortisone, prednisone, sodium valproate, nifedipine, 
diltiazem, amiodarone, alcohol, labetolol, and chemotherapy). 
 
Three variables were found to increase the odds of respondents suffering from 
myopathy. The model only accounted for 11.0 % to 14.7% of the variance in the 
dependent variable, which may be due to the relatively modest response rate of the 
respondent in the survey, and also the limited numbers of explanatory variables in 
explaining the incidence of myopathy.  The “goodness of fit test” has a highly 
significant Chi-square value at 41.142 with 4 degrees of freedom (P<0.001). The model 
correctly identifies 72.9% of cases that suffered from myopathy and 48.3% who did not. 
Therefore the positive predictive value is 65.4% and the negative predictive value is 
57%. Table 4.10 displays the extent to which the variables influenced the outcome 
variable.  
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Table 4.10 Variables in the Equation 
 
Statistical analysis with multiple logistic regression found that increasing in age, having 
heart failure and taking cortisone-like drugs increased statin users susceptible to 
myopathy. Table 4.10 column Exp (β) shows that, for every 1-year increase in age, the 
odds of suffering from myopathy increased 1.039 (95% CI 1.019 – 1.061).  Furthermore, 
taking cortisone-like medication increased the odds of suffering myopathy 16.4 times 
(95% CI; 2.2 – 124.3), while participants with heart failure were 9.3 times (95% CI 1.2 – 
73.2) more likely to develop muscle symptoms when prescribed statins. 
 
 
 
 4.2.COENZYME Q10 FOR MUSCLE CRAMPS STUDY 
 
 4.2.1 Recruitment 
A total of 61 participants initially enrolled into the study, 35 people in Group A (statin 
users) and 26 people in Group B (non-statin users). In the middle of the study, six 
participants withdrew for the following reasons:   
 
95% CI Variable β 
(SE) 
p value Exp (β) 
Lower Upper 
Age 0.039 
(0.010) 
0.000 1.039 1.019 1.061 
Heart failure 2.288 
(1.054) 
0.034 9.285 1.177 73.217 
Cortisone-like drugs 2.793 
(1.034) 
0.007 16.388 2.161 124.299 
Sodium valproate -2.989 
(1.752) 
0.088 0.050 0.002 1.560 
Constant -2.246 
(0.639) 
0.000 0.106 - - 
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1. Two participants from the Group B and one participant from Group A withdrew 
during the assessment periods without stating reasons. 
2. One participant from the Group B experienced a skin rash while taking placebo (on 
day 5 of the 2nd week of the study), and decided to withdraw from the trial, and was 
given antihistamine by the participant’s doctor. The Primary Investigator was later 
informed since the participant commenced the trial in spring, participant’s allergy 
was most probably caused by pollen, not the medicine (placebo).  
3. One participant from the Group A decided to withdraw because the participant 
wanted to continue taking CoQ10 during the wash out period. The participant later 
decided to buy CoQ10 from a pharmacy and started taking it regularly.  
4. One participant from the Group A fell out of the bed, and doctor advised the 
participant to rest (and to start taking NSAID), and the participant later withdrew 
from the study. 
 
 
Thirty-two participants in Group A and 23 participants in Group B completed the study. 
Data from two participants in Group A were excluded from analysis for the following 
reasons: 
 
1. One participant did not experience any cramps during the 6 weeks study period, 
despite having cramps before the study was commenced.  
2. One participant experienced the death of sibling in the middle of the study, and then 
suffered from stress, and felt this increased the condition of cramps.   
 
 
As a result, there were 30 participants in the Group A and 23 participants in the Group B 
included in statistical analysis. Flow diagram of the study is summarized in Figure 4.2. 
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Figure 4.2 Flow Diagram of Clinical Trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Registered or Eligible Participants (N=61) 
Participants were separated into two groups 
35 participants in Group A 
(Statin Group) 
26 participants in Group B 
(Control Group) 
1 dropout during the 
assessment period 
2 dropouts during the 
assessment period 
34 took CoQ10 during  
Weeks 2 and 3 
24 took placebo during  
Weeks 2 and 3 
1 dropout during Week 2 1 dropout during Week 2 
1 dropout during washout 
period, and 32 followed-up 
during wash out period 
23 followed-up during wash 
out period 
32 took placebo during  
Weeks 5 and 6 
23 took CoQ10 during  
Weeks 5 and 6 
32 completed the trial. 30 were 
included in analysis 
23 completed the trial. All of 
them were included in analysis 
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4.2.2 Patient Demographics 
The gender mix in the two groups (Table 4.11) was significantly different with the 
majority of the Group A being females and the majority of the Group B being males (p = 
0.003). 
 
Table 4.11 The Age and Gender of Participants 
 
Group 
 
Number  
(and gender) 
 
Mean of Age (SD) 
(Years) 
 
p value 
A 
(Statin) 
 
30 (7 Male and 23 Female) 
 
64.5 (8.4) 
B 
(Control) 
 
23 (17 Male and 6 Female) 
 
58.0 (11.2) 
 
0.021 
 
 
After testing the data for equality of variance, t testing for the equality of the mean was 
undertaken. This demonstrated that participants in the Group A were significantly older 
than those in Group B (mean difference = 9.17 years; 95% CI: 1.02-11.83). Further 
testing with the Shapiro-Wilk test confirmed that the data of age of participants were 
normally distributed.  
 
Of the total of 53 participants, 11 (20.8%) reported having a family history associated 
with muscle cramps. Moreover, 41 (77.4%) reported having cramps at least once a week, 
and 38 (71.7%) reported experiencing cramps for over 5 years.  
 
In Group A (statin group), atorvastatin 10 mg, was reported as the most commonly 
prescribed statin, accounting for 30% (Table 4.12). 
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Table 4.12 Statin Therapy Used in Group A 
Statin Used Number of Respondents Proportion of Respondents 
Atorvastatin 10 mg 9 30.0 
Atorvastatin 20 mg 5 16.7 
Atorvastatin 40 mg 5 16.7 
Atorvastatin80 mg 3 10.0 
Fluvastatin 20 mg 1 3.3 
Pravastatin 20 mg 2 6.7 
Pravastatin 80 mg 1 3.3 
Simvastatin 10 mg 2 6.7 
Simvastatin 20 mg 1 3.3 
Simvastatin 80 mg 1 3.3 
Total   30 100 
 
 
In the Group A, beside statins, alcohol was the most commonly consumed drug 
associated with myopathy; making up 11 (36.7%) cases, while in the Group B, 
magnesium became the most frequently used drug, accounting for 13 (56.5%) cases. 
(Table 4.13) 
 
Furthermore, none of participants in the Group B (Group B) suffered from 
hypercholesterolaemia. The most commonly disease suffered by participants in both 
group was hypertension, accounting for 11 cases (20.8% of total participants) [Table 
4.14]. 
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Table 4.13 Drugs Associated with Myopathy Taken by Participants   
Group  
Drug Used Group A 
(Statin Users 
n=30) 
n (%) 
Group B 
(Non-Statin 
Users n=23) 
n (%) 
Number of 
Respondents 
Proportion of 
Total 
Participants  
(n = 53) 
(%) 
Alcohol 11 (36.7%) 4 (17.4%) 15 28.3 
Cortisone 3 (10%) 1 (4.3%) 4 7.5 
Prednisone/Prednisolone 1 (3.3%) 0 (0%) 1 1.9 
Thyroxine 2 (6.7%) 2 (8.7%) 4 7.5 
Calcium 6 (20%) 10 (43.3%) 16 30.2 
Magnesium 8 (26.7%) 13 (56.5%) 21 39.6 
Vitamin D 3 (10%) 8 (34.8%) 11 20.7 
Vitamin E 4 (13.3%) 8 (34.8%) 12 22.6 
None 10 (33.3%) 4 (17.4%) 14 26.4 
Total 48 (160%) 50 (217.4%) 98 185 
 
 
 
Table 4.14 Disease Suffered by Participants 
Group  
Disease Suffered Group A 
(Statin Users 
n=30) 
n (%) 
 
Group B 
(Non-Statin Users 
n=23) 
n (%) 
 
Number of 
Respondents 
 
Proportion of 
Total 
Participants  
(n = 53)  
(%) 
Hypertension 3 (10%) 8 (34.8%) 11 20.8 
Diabetes Mellitus 3 (10%) 2 (8.7%) 5  9.4 
Ischaemic Heart 
Disease 
2 6.7(%) 0 (0%) 2 3.8 
Hypothyroidism 2 (6.7%) 2 (8.7%) 4 7.5 
None 20 (66.7%) 14 (60.9%) 34 64.2 
Total 30 (%) 26 (%) 56 105.7 
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4.2.3 Part of the Body Affected by Cramps 
During the study, it was found that the majority of participants reported their calves as 
the most commonly affected area of the body (34; 64.2% of total participants), while the 
fingers were reported as the least affected area of the body, only making up 1 case (1.9% 
of total participants) [Table 4.15]. 
 
Table 4.15 Part of the Body Affected During The Study 
Group Part of the Body 
Affected Group A 
(Statin Users 
n=30) 
n (%) 
Group B 
(Non-Statin Users 
n=23) 
n (%) 
Number of 
Respondents 
Proportion of 
Total 
Participants  
(n = 53) 
(%) 
Calves 20 (66.7%) 14 (60.9%) 34 64.2 
Thigh and buttocks 12 (40%) 6 (26.1%) 18 34.0 
Back 5 (16.7%) 5 (21.7%) 10 18.9 
Feet 7 (23.3%) 9 (39.1%) 16 30.2 
Ankles 1 (3.3%) 1 (4.3%) 2 3.8 
Toes 2 (6.7%) 0 (0%) 2 3.8 
Knees 2 (6.7%) 0 (0%) 2 3.8 
Legs 5 (16.7%) 15 (65.2%) 20 37.7 
Arms 4 (13.3%) 2 8.7(%) 6 11.3 
Hands 3 (10%) 1 (4.3%) 4 7.5 
Fingers 1 (3.3%) 0 (0%) 1 1.9 
Neck 1 (3.3%) 1 (4.3%) 2 3.8 
Shoulders  1 (3.3%) 1 (4.3%) 2 3.8 
Total respondents 64 (213.3%) 55 (239.1%) 119 224.7 
 
 
4.2.4 Adverse Events with CoQ10 
It was reported that there were no significant differences in the adverse events frequency 
between CoQ10 and placebo in both statin users (Group A) and non-statin users (Group 
B). The following symptoms were reported by participants in Group A whilst they were 
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on either CoQ10 or placebo: nausea, stomach upset, and insomnia. In Group B, 
participants reported having flu-like symptoms and nausea when they were on CoQ10; 
and having headache and nausea when they were on placebo (Table 4.16). There were 
no participants who had multiple subjective symptoms, and these symptoms stopped 
without requiring any treatment. 
 
Table 4.16 Adverse Events with CoQ10 and Placebo 
Group A Group B  
Symptoms CoQ10 
n (%) 
Placebo 
n (%) 
CoQ10 
n (%) 
Placebo 
n (%) 
Nausea 1 (3.3%) 1 (4.3%) 1 (3.3%) 1 (4.3%) 
Stomach upset 1 (3.3%) 1 (4.3%) 0 (0%) 0 (0%) 
Flu-like symptoms 0 (0%) 0 (0%) 1 (3.3%) 0 (0%) 
Headache  0 (0%) 0 (0%) 0 (0%) 1 (4.3%) 
Insomnia 1 (3.3%) 1 (4.3%) 0 (0%) 0 (0%) 
 
  
4.2.5 Co-Enzyme Q10 Efficacy 
The efficacy of co-enzyme Q10 was assessed on the basis of changes in the following: 
• The average number of days per week participants suffered muscle cramps 
• The average number of muscle cramps suffered per week 
• The intensity of the pain associated with the muscle cramps 
• The average duration of the cramps suffered per week 
 
 
4.2.5.1 Days with muscle cramps 
 
4.2.5.1.1 Group A – Statin Users 
Table 4.17 below shows the number of days per week each patient in the Group A 
reported suffering muscle cramps across the 6 weeks of the study; which varied 
considerably between the participants. 
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Table 4.17 Group A – Days per week with muscle cramps 
Days per week with muscle cramp 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
Patient No. Baseline Co-Enzyme Q10 Washout Placebo 
1 3 2 2 4 3 5 
2 5 2 3 5 2 2 
3 5 4 4 5 5 6 
4 2 0 1 2 1 1 
5 7 7 7 7 7 7 
6 4 1 1 2 2 1 
7 7 7 7 7 7 7 
8 1 2 2 1 0 0 
9 4 5 4 3 5 5 
10 3 5 4 3 2 4 
11 5 4 2 5 3 4 
12 7 6 6 7 6 5 
13 1 0 0 1 0 1 
14 3 1 0 1 2 1 
15 6 6 6 6 4 4 
16 2 1 1 2 1 2 
17 2 1 1 4 3 2 
18 3 0 1 2 2 2 
19 7 6 6 6 4 4 
20 6 3 3 5 4 5 
21 0 0 0 1 0 1 
22 7 3 3 5 4 3 
23 3 3 1 2 2 2 
24 2 1 1 2 2 2 
25 2 1 2 1 1 1 
26 2 1 1 1 3 3 
27 2 2 1 3 3 3 
28 4 2 3 6 5 4 
29 3 4 4 2 3 4 
30 2 1 2 3 4 3 
MEAN 3.7 2.7 2.6 3.5 3.0 3.1 
SD 2.1 2.2 2.1 2.0 1.9 1.9 
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As an overall trend, the average numbers of days per week with muscle cramps were 
lowest when the participants received CoQ10 100 mg daily (Weeks 2 and 3), and highest 
when they were not on a trial “medication” (i.e. either CoQ10 or placebo), that being the 
baseline period (Week 1) and the wash out period (Week 4). On average, participants 
suffered more days with cramps during the time they were on placebo (Week 5 and 6) 
than on CoQ10 (Weeks 2 and 3), but less that when they were on no medication at all 
(Weeks 1 and 4) (Table 4.17).  
 
Amongst the 30 participants in the Group A, 19 people (63.3%) showed positive 
responses with CoQ10 (i.e. they experienced fewer days with muscle cramps) while 
eight people (26.7%) showed positive responses with placebo. The remaining three 
participants (10%) did not experience any differences in their leg cramp frequency on 
either CoQ10 or placebo. 
 
Repeated Measures ANOVA was performed to determine whether or not there were any 
differences in the number of days per week with muscle cramps in the Group A over a 6-
week period of time. The data were found to have violated the sphericity assumption 
(the variances across the weeks were not equal), thus Greenhouse-Geisser correction 
was then used to provide a valid F-ratio97. It was then found that the frequency of muscle 
cramps differed significantly over the 6 weeks of the study, with F (3.391, 98.351) = 
6.407, p= 0.000 (using Greenhouse-Geisser correction).  
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the frequency of muscle cramps between the weeks of the study (Table 4.18). Here (I) 
equals the index week and (J) the comparator week. A result in (I – J) represents mean 
difference in the muscle cramp frequency between weeks. Those differences marked 
with an asterisk are statistically significant at the 0.05 levels. 
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Table 4.18 Group A- Significant Inter-Week Differences in Cramp Frequency as Identified 
by Scheffè testing   
 
95% Confidence Interval for Difference (a)
(I) Week (J) Week
Mean Difference (I-J)
Lower Bound 
SE 
 
p value (a) 
 Lower Bound Upper Bound 
2 0.967(*) 0.251 0.001 0.453 1.481 
3 1.033(*) 0.232 0.000 0.558 1.509 
4 0.200 0.188 0.297 -0.185 0.585 
5 0.667(*) 0.237 0.009 0.183 1.150 
1 
6 0.533 0.274 0.062 -0.028 1.094 
1 -.967(*) 0.251 0.001 -1.481 -0.453 
3 0.067 0.143 0.645 -0.226 0.360 
4 -.767(*) 0.270 0.008 -1.319 -0.215 
5 -0.300 0.263 0.264 -0.838 0.238 
2 
6 -0.433 0.238 0.079 -0.921 0.054 
1 -1.033(*) 0.232 0.000 -1.509 -0.558 
2 -0.067 0.143 0.645 -0.360 0.226 
4 -0.833(*) 0.230 0.001 -1.304 -0.362 
5 -0.367 0.237 0.133 -0.852 0.119 
3 
6 -0.500(*) 0.234 0.041 -0.978 -0.022 
1 -0.200 0.188 0.297 -0.585 0.185 
2 0.767(*) 0.270 0.008 0.215 1.319 
3 0.833(*) 0.230 0.001 0.362 1.304 
5 0.467(*) 0.208 0.032 0.042 0.891 
4 
6 0.333 0.237 0.169 -0.150 0.817 
1 -0.667(*) 0.237 0.009 -1.150 -0.183 
2 0.300 0.263 0.264 -0.238 0.838 
3 0.367 0.237 0.133 -0.119 0.852 
4 -0.467(*) 0.208 0.032 -0.891 -0.042 
5 
6 -0.133 0.157 0.403 -0.455 0.188 
1 -0.533 0.274 0.062 -1.094 0.028 
2 0.433 0.238 0.079 -0.054 0.921 
3 0.500(*) 0.234 0.041 0.022 0.978 
4 -0.333 0.237 0.169 -0.817 0.150 
6 
5 0.133 0.157 0.403 -0.188 0.455 
Based on estimated marginal means 
* The mean difference is significant at the .05 level. 
a Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffè test showed there was a significant difference in the number of days per 
week with muscle cramp during the time when participants were on no medication 
(Weeks 1 and 4), on CoQ10 (Weeks 2 and 3) and on placebo (Weeks 5 and 6). 
Furthermore, there was a significant difference between the number of days per week 
with muscle cramps in Week 3 (the second week participants received CoQ10) and that 
in Week 6 (the second week participants received placebo), p<0.05.  
 
Further thorough testing using t-paired analysis was performed to determine whether 
there were any differences in the frequency of muscle cramps between the two 
medication periods, namely the periods participants were on CoQ10 (Weeks 2 + 3) and 
the periods they were on placebo (Weeks 5 + 6). From t-paired analysis, on average, 
participants suffered fewer days with cramps during the periods they were on CoQ10 
(Weeks 2 + 3; mean score= 5.33 ± 0.77 days) than on placebo (Weeks 5 + 6; mean 
score= 6.13 ± 0.67 days). However, the differences were not statistically significant 
(t(29) = -1.827, 95% CI= -1.696 – 0.096; p=0.078)   
 
 
4.2.5.1.2 Group B –non-statin users (Controls) 
Table 4.19 below shows the number of days per week each patient in the Group B 
reported muscle cramps across the 6 weeks of the study, which varied considerably 
between the participants. 
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Table 4.19 Group B – Days per week with muscle cramps 
Days per week with muscle cramps 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline Placebo Washout CoQ10 
1 6 3 2 2 2 6 
2 6 6 7 6 6 5 
3 4 2 3 3 1 1 
4 5 4 3 5 3 5 
5 2 1 1 1 1 0 
6 1 1 1 2 1 1 
7 6 5 5 6 6 6 
8 5 4 5 4 3 3 
9 1 0 0 2 2 1 
10 4 3 5 6 4 3 
11 3 2 2 4 2 3 
12 3 5 3 4 4 2 
13 4 3 5 3 4 4 
14 3 1 2 2 1 1 
15 2 1 1 2 1 0 
16 6 6 5 6 4 4 
17 4 2 3 3 4 2 
18 4 4 2 3 1 2 
19 5 4 2 4 2 2 
20 4 2 2 2 1 2 
21 7 6 5 6 7 5 
22 5 4 6 5 7 7 
23 7 6 4 6 6 6 
MEAN 4.2 3.3 3.2 3.8 3.2 3.1 
SD 1.7 1.9 1.9 1.7 2.1 2.1 
 
 
In general, the average numbers of days per week with muscle cramps were lowest when 
the participants received CoQ10 100 mg (Weeks 5 and 6), and highest when they were 
not on medication, namely the baseline period (Week 1) and the wash out period (Week 
4). On average, participants suffered less cramps when they were on placebo (Weeks 2 
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and 3) than on the baseline and washout periods (Weeks 1 and 4), but slightly more than 
when they were on CoQ10 (Weeks 2 and 3) [Table 4.19]. 
 
Amongst the 23 participants in the Group B, 11 (47.8%) showed positive responses with 
CoQ10 (i.e. they experienced fewer days with muscle cramps), and 10 (43.5%) 
experienced positive responses with placebo. The remaining two participants (8.7%) did 
not experience any differences in the number days per week with muscle cramps with 
both CoQ10 and placebo. 
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the number of days per week with muscle cramps in the Group 
B over a 6-week period of time. This demonstrated that the frequency of muscle cramps 
differed significantly over the 6 weeks of the study, with F (5,110) = 5.93, p=0.000. 
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the frequency of muscle cramps between the weeks of study (Table 4.20).   
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Table 4.20: Group B- Significant Inter-Week Differences in Cramp Frequency as 
Identified by Scheffè testing  
 
95% Confidence Interval for Difference (a)  (I) 
Week 
(J) 
Week 
Mean Difference (I-
J) 
SE 
 
p value (a) 
 Lower Bound Upper Bound 
2 0.957(*) .204 0.000 0.534 1.379 
3 1.000(*) .281 0.002 0.417 1.583 
4 0.435 .258 0.106 -0.100 0.970 
5 1.043(*) .324 0.004 0.373 1.714 
1 
6 1.130(*) .254 0.000 0.604 1.657 
1 -0.957(*) .204 0.000 -1.379 -0.534 
3 0.043 .270 0.874 -0.517 0.604 
4 -0.522(*) .207 0.020 -0.952 -.092 
5 0.087 .294 0.770 -0.523 0.697 
2 
6 0.174 .312 0.583 -0.473 0.821 
1 -1.000(*) .281 0.002 -1.583 -0.417 
2 -0.043 .270 0.874 -0.604 0.517 
4 -0.565(*) .234 0.024 -1.050 -0.080 
5 0.043 .247 0.862 -0.469 0.556 
3 
6 0.130 .316 0.684 -0.525 0.786 
1 -0.435 .258 0.106 -0.970 0.100 
2 0.522(*) .207 0.020 0.092 0.952 
3 0.565(*) .234 0.024 0.080 1.050 
5 0.609(*) .249 0.023 0.091 1.126 
4 
6 0.696(*) .311 0.036 0.051 1.340 
1 -1.043(*) .324 0.004 -1.714 -0.373 
2 -0.087 .294 0.770 -0.697 0.523 
3 -0.043 .247 0.862 -0.556 0.469 
4 -0.609(*) .249 0.023 -1.126 -0.091 
5 
6 0.087 .281 0.760 -0.495 0.669 
1 -1.130(*) .254 0.000 -1.657 -0.604 
2 -0.174 .312 0.583 -0.821 0.473 
3 -0.130 .316 0.684 -0.786 0.525 
4 -0.696(*) .311 0.036 -1.340 -0.051 
6 
5 -0.087 .281 0.760 -0.669 0.495 
Based on estimated marginal means 
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffè test showed there was a significant difference in the number of days per 
week with muscle cramps during the time when participants were on no medication 
(Weeks 1 and 4) and on CoQ10 (Weeks 5 and 6), and placebo (Weeks 2 and 3); p<0.05. 
Further t-test (paired analysis) was performed to determine whether there were any 
differences in the frequency of muscle cramps between the two medication periods, 
namely the periods when participants were on CoQ10 (Weeks 5 + 6) and those when 
they were on placebo (Weeks 2 + 3). From t-paired analysis, on average, participants 
suffered more days with cramps during the periods they were on placebo (Weeks 2 + 3; 
mean score= 6.486 ± 0.73), than on CoQ10 (Weeks 5 + 6; mean score = 6.26 ± 0.83). 
However, these differences were not statistically significant (t (22) = 0.494; (95% CI= -
0.695 – 1.130; p=0.626). 
 
 
4.5.2.2 Number of muscle cramps 
4.5.2.2.1 Group A - Statin group 
Table 4.21 below shows the number of muscle cramps per week suffered by each patient 
in the Group A, which varied considerably across the participants. 
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Table 4.21 Group A – Number of muscle cramps per week 
Number of muscle cramps per week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
Patient No Baseline CoQ10 Washout Placebo 
1 5 4 5 6 5 5 
2 5 2 3 5 2 2 
3 10 7 7 9 9 10 
4 4 0 2 2 3 2 
5 15 13 11 11 12 12 
6 4 1 1 3 4 3 
7 7 7 7 7 7 7 
8 1 2 2 1 0 0 
9 4 6 5 4 7 6 
10 3 5 4 4 3 3 
11 7 6 4 7 8 7 
12 11 11 10 12 8 8 
13 1 0 0 1 0 1 
14 3 1 0 1 2 1 
15 7 9 8 7 5 5 
16 2 1 1 2 1 2 
17 2 1 1 4 3 2 
18 3 0 1 2 2 2 
19 8 8 7 6 6 5 
20 7 5 4 8 5 6 
21 0 0 0 1 0 1 
22 8 5 5 8 7 8 
23 3 3 1 2 3 2 
24 2 1 1 2 2 2 
25 2 1 2 1 1 1 
26 3 2 1 3 4 4 
27 2 2 2 3 4 3 
28 4 2 3 6 5 5 
29 3 5 5 2 3 4 
30 2 1 2 3 4 3 
MEAN 4.6 3.7 3.5 4.4 4.2 4.1 
SD 3.4 3.5 3.0 3.0 2. 9 2.9 
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In general, the average numbers of muscle cramps per week were highest when 
participants were on no medication (Weeks 1 and 4), and lowest when they were on 
CoQ10 100 mg (Weeks 2 and 3). Furthermore, participants suffered less cramps when 
they were on placebo (Weeks 5 and 6) than on the baseline and washout periods (Weeks 
1 and 4), but more than when they were on CoQ10 (Weeks 2 and 3) [Table 4.21].  
 
Of the 30 participants in the Group A, 20 (66.7%) showed positive responses to CoQ10 
(i.e. they experienced fewer cramps) while eight of them (26.7%) experienced positive 
responses to placebo. The remaining two participants (6.7%) did not experience any 
differences in their cramps frequency with both CoQ10 and placebo. 
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the number of cramps in the Group A over a 6-week period of 
time. The data were found to have violated the sphericity assumption (the variances 
across the weeks were not equal), thus Greenhouse-Geisser correction was then used to 
provide a valid F-ratio97. It was then found that the number of cramps was significantly 
different over the weeks of treatment, F (3.015, 87.440) = 4.609, p=0.005 (using 
Greenhouse-Geisser correction). 
 
Scheffè testing was then undertaken to determine where the significant differences 
existed in the numbers of muscle cramps between the weeks of study (Table 4.22).   
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Table 4.22 Group A- Significant Inter-Week Differences in the number of muscle cramps 
as Identified by Scheffè testing  
 
95% Confidence Interval for Difference (a) 
 (I) Week (J) Week Mean Difference (I-J) 
SE 
 
p value (a) 
 Lower Bound Upper Bound 
2 0.900(*) 0.301 0.006 0.285 1.515 
3 1.100(*) 0.281 0.001 0.525 1.675 
4 0.167 0.235 0.484 -0.315 0.648 
5 0.433 0.270 0.119 -0.119 0.985 
1 
6 0.533(*) 0.252 0.043 0.017 1.050 
1 -0.900(*) 0.301 0.006 -1.515 -0.285 
3 0.200 0.182 0.281 -0.172 0.572 
4 -0.733(*) 0.332 0.035 -1.412 -0.054 
5 -0.467 0.345 0.186 -1.172 0.239 
2 
6 -0.367 0.334 0.281 -1.049 0.316 
1 -1.100(*) 0.281 0.001 -1.675 -0.525 
2 -0.200 0.182 0.281 -0.572 0.172 
4 -0.933(*) 0.283 0.003 -1.513 -0.354 
5 -0.667(*) 0.316 0.043 -1.312 -0.021 
3 
6 -0.567 0.294 0.064 -1.169 0.035 
1 -0.167 0.235 0.484 -0.648 0.315 
2 0.733(*) 0.332 0.035 0.054 1.412 
3 0.933(*) 0.283 0.003 0.354 1.513 
5 0.267 0.271 0.333 -0.287 0.821 
4 
6 0.367 0.237 0.133 -0.119 0.852 
1 -0.433 0.270 0.119 -0.985 0.119 
2 0.467 0.345 0.186 -0.239 1.172 
3 0.667(*) 0.316 0.043 0.021 1.312 
4 -0.267 0.271 0.333 -0.821 0.287 
5 
6 0.100 0.139 0.476 -0.183 0.383 
1 -0.533(*) 0.252 0.043 -1.050 -0.017 
2 0.367 0.334 0.281 -0.316 1.049 
3 0.567 0.294 0.064 -0.035 1.169 
4 -0.367 0.237 0.133 -0.852 0.119 
6 
5 -0.100 0.139 0.476 -0.383 0.183 
Based on estimated marginal means  
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffè test showed there were significant differences in the number of muscle 
cramps between Week 1 (the baseline period) and Weeks 2 and 3 (CoQ10 period) and 
also Week 6 (placebo period). It was also revealed that the number of muscle cramps 
differed significantly between the washout period (Week 4) and CoQ10 period (Weeks 2 
and 3). Furthermore, there was a significant difference in cramps numbers between 
Week 3 (the second week when participants received CoQ10) and week 5 (the first week 
when participants received placebo), with p<0.05.   
 
Further thorough testing using t-paired analysis was performed to determine whether 
there were any differences in the number of muscle cramps between two medication 
periods, namely the periods when participants were on CoQ10 (Weeks 2 + 3) and those 
when they were on placebo (Weeks 5 + 6). From t-paired analysis, on average, 
participants suffered fewer muscle cramps during the periods they were on CoQ10 
(Weeks 2 + 3; mean score= 7.20 ± 1.16), than on placebo (Weeks 5 + 6; mean score= 
8.23 ± 1.05). However, these differences were not statistically significant (t(29)= -1.712, 
95% CI= -2.268 – 0.201; p=0.098).  
 
 
4.2.5.2.2 Group B – non statin users (Controls) 
Table 4.23 below presents the number of cramps per week suffered by each patient in 
the Group B over the 6 weeks of the study, which varied considerably between the 
participants. 
 
In general, the average numbers of muscle cramps per week were highest when they 
were on no medication, namely the baseline period (Week 1) and the wash out period 
(Week 4), and lowest when they were on CoQ10 100 mg daily (Weeks 5 and 6).  On 
average, participants suffered slightly more muscle cramps when they were on placebo 
(Weeks 2 and 3) than on COQ10, but less that when they were on no medication at all 
(Weeks 1 and 4) [Table 4.23]. 
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Table 4.23 Group B – Number of muscle cramps per week  
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient No 
Baseline Placebo Washout CoQ10 
1 6 3 3 4 2 6 
2 10 9 8 9 8 7 
3 3 2 2 3 1 1 
4 13 14 13 15 14 16 
5 3 2 1 1 1 0 
6 1 1 1 2 1 1 
7 12 10 10 12 11 11 
8 6 6 7 6 6 5 
9 2 0 0 2 2 0 
10 4 4 6 6 5 5 
11 3 3 2 4 2 3 
12 6 5 5 6 4 4 
13 9 7 8 9 7 6 
14 3 1 2 2 1 1 
15 2 2 1 4 1 0 
16 10 9 9 10 9 10 
17 5 2 3 4 4 2 
18 5 4 2 3 3 2 
19 6 4 4 5 3 3 
20 4 3 3 3 1 2 
21 12 10 9 12 11 9 
22 9 7 8 9 8 8 
23 11 8 8 10 9 9 
MEAN 6.3 5.0 5.0 6.1 5.0 4.8 
SD 3.7 3.6 3.6 3.7 3.9 4.2 
 
 
Of the 23 people assigned to Group B, 11 of them (47.8%) noted that they experienced 
fewer cramps when they were on CoQ10 (Weeks 5 and 6); whereas, nine people 
(39.1%) reported they had fewer cramps while they were on placebo. The remaining 
three participants (13%) did not experience any differences in their cramp frequency 
with both CoQ10 and placebo.   
 
 
 
  Number of muscle cramps per week 
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Table 4.24 Group B- Significant Inter-Week Differences in the numbers of muscle cramps 
as Identified by Scheffè testing 
 
95% Confidence Interval for Difference(a)  (I)  
Week 
(J)   
Week 
Mean Difference 
(I-J) SE P value (a) 
Lower Bound Upper Bound 
2 1.261(*) 0.229 0.000 0.787 1.735 
3 1.304(*) .0263 0.000 0.760 1.849 
4 0.174 .0249 0.492 -0.342 0.690 
5 1.348(*) .0256 0.000 0.816 1.879 
1 
6 1.478(*) .0326 0.000 0.802 2.154 
1 -1.261(*) .0229 0.000 -1.735 -0.787 
3 0.043 .0194 0.824 -0.358 0.445 
4 -1.087(*) .0198 0.000 -1.497 -0.676 
5 0.087 .0226 0.704 -0.382 0.555 
2 
6 0.217 .0281 0.447 -0.365 0.800 
1 -1.304(*) .0263 0.000 -1.849 -0.760 
2 -0.043 .0194 0.824 -0.445 0.358 
4 -1.130(*) .0202 0.000 -1.549 -0.712 
5 0.043 .0222 0.847 -0.417 0.504 
3 
6 0.174 .0279 0.539 -0.404 0.752 
1 -0.174 .0249 0.492 -0.690 0.342 
2 1.087(*) .0198 0.000 0.676 1.497 
3 1.130(*) .0202 0.000 0.712 1.549 
5 1.174(*) .0174 0.000 0.813 1.535 
4 
6 1.304(*) .0263 0.000 0.760 1.849 
1 -1.348(*) .0256 0.000 -1.879 -0.816 
2 -0.087 .0226 0.704 -0.555 0.382 
3 -0.043 .0222 0.847 -0.504 0.417 
4 -1.174(*) .0174 0.000 -1.535 -0.813 
5 
6 0.130 .0283 0.650 -0.457 0.718 
1 -1.478(*) .0326 0.000 -2.154 -0.802 
2 -0.217 .0281 0.447 -0.800 0.365 
3 -0.174 .0279 0.539 -0.752 0.404 
4 -1.304(*) .0263 0.000 -1.849 -0.760 
6 
5 -0.130 .0283 0.650 -0.718 0.457 
Based on estimated marginal means 
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the number of cramps in the Group B over the 6-week period of 
time. This identified that the number of cramps differed significantly over the 6 weeks of 
the study, with F (5,110) = 14.273, p=0.000. 
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the numbers of muscle cramps between the weeks of the study (Table 4.24). The 
Scheffè test showed that the number of cramps on the baseline period (Weeks 1) and the 
washout period (Week 4) was significantly different, and much higher than cramp 
numbers on COQ10 periods (Weeks 2 and 3) and placebo periods (Weeks 5 and 6), with 
p<0.01.   
 
Further thorough testing using t-paired analysis was performed to determine whether 
there were any differences in the number of cramps between the two medication periods, 
namely the periods when participants were on CoQ10 (Weeks 5 + 6) and those when 
they were on placebo (Weeks 2 + 3).  From t-paired analysis, on average, participants 
suffered more muscle cramps during the periods they were on placebo (Weeks 2 + 3; 
mean score= 10.04 ± 1.49), than on CoQ10 (Weeks 5 + 6; mean score= 9.78 ± 1.67). 
However, the differences were not statistically significant (t (22) = 0.699, 95% CI= -
0.513 – 1.035; p= 0.492).  
 
 
4.2.5.3. Average Pain Score Associated with Muscle Cramps 
4.2.5.3.1 Group A - Statin Group 
Table 4.25 below presents the mean of the average weekly pain scores associated with 
the muscle cramps from each statin user across the 6 weeks of the study. 
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Table 4.25 Group A – Mean of average pain scores per week 
Mean of average pain score per week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline CoQ10 Washout Placebo 
1 7.2 6.0 6.5 7.0 7.0 7.3 
2 4.0 4.0 5.0 6.0 5.0 4.0 
3 2.7 2.2 1.2 1.5 1.4 2.7 
4 3.0 0.0 1.0 2.0 3.0 2.0 
5 2.4 1.5 1.4 1.4 1.7 1.4 
6 1.0 2.0 1.0 1.0 1.0 1.0 
7 2.0 1.0 1.0 2.0 2.0 2.0 
8 3.0 3.0 2.5 2.0 0 0 
9 3.3 3.3 3.2 3.0 4.1 3.8 
10 5.0 3.4 3.3 5.0 4.3 4.7 
11 2.6 2.0 1.0 2.4 2.3 2.8 
12 3.4 5.0 5.0 3.8 3.0 3.0 
13 2.0 0.0 0 3.0 0 1.0 
14 2.0 1.5 0 2.0 2.0 1.5 
15 5.8 5.0 6.0 5.0 5.0 5.0 
16 7.0 6.0 5.0 6.0 8.0 7.0 
17 9.0 7.5 7.0 10 9.0 8.0 
18 1.0 0.0 1.0 2.0 1.0 1.0 
19 6.5 5.0 4.5 5.0 6.0 7.0 
20 6.0 4.0 4.0 4.0 5.0 4.0 
21 0 0 0 1.0 0.0 2.0 
22 4.0 3.0 3.0 3.5 4.0 4.0 
23 2.0 2.0 2.0 4.0 2.0 3.0 
24 8.0 6.0 5.5 7.0 8.0 7.0 
25 3.0 4.0 2.0 2.0 2.0 2.0 
26 4.5 3.7 3.5 3.8 4.0 4.0 
27 6.5 7.0 6.0 6.0 7.0 8.0 
28 4.0 3.0 3.0 6.0 5.0 5.0 
29 3.0 5.0 5.0 3.0 3.0 3.0 
30 5.0 2.0 3.0 4.0 5.0 3.0 
MEAN 4.0 3.3 3.0 3.8 3.7 3.7 
SD 2.2 2.1 2.1 2.1 2.5 2.3 
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As an overall trend, the mean of the average daily pain score associated with the muscle 
cramps per week was lowest when participants were on CoQ10 100 mg daily (Weeks 2 
and 3), and highest when they were on no medication, namely the baseline period (Week 
1) and the wash out period (Week 4). On average, participants experienced a lower mean 
average daily pain score when they were on placebo (Weeks 5 and 6) than the baseline 
and the washout periods, but higher than when they were on CoQ10 therapy.   
 
It is found while seven of the 30 people (23.3%) in the Group A noted their pain scores 
were lower when they were on placebo, 22 of them (73.3%) pointed out they had a 
minimal pain score with CoQ10. On the other hand, one person (3.3%) noted not 
experiencing any difference in the average pain score with both CoQ10 and placebo.   
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the average pain score associated with the muscle cramps in the 
Group A over the 6-week period of time.  The data were found to have violated the 
sphericity assumption (the variances across the weeks were not equal), thus Greenhouse-
Geisser correction was then used to provide a valid F-ratio97. The results show that the 
average pain score was significantly different over the weeks of treatment, F (3.234, 
93.784) = 5.191, p=0.002 (using Greenhouse-Geisser correction). 
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the average pain score associated with the muscle cramps between the weeks of study 
(Table 4.26).   
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Table 4.26 Group A- Significant Inter-Week Differences in Average Pain Scores as 
Identified by Scheffè testing 
95% Confidence Interval for Difference (a) (I)  
Week 
(J)   
Week 
Mean Difference (I-J)
 
SE 
 
p value (a) 
 
Lower Bound Upper Bound 
2 0.693(*) 0.217 0.003 0.250 1.136 
3 0.877(*) 0.208 0.000 0.452 1.301 
4 0.150 0.192 0.440 -0.242 0.542 
5 0.270 0.155 0.091 -0.046 0.586 
1 
6 0.290 0.188 0.133 -0.094 0.674 
1 -0.693(*) 0.217 0.003 -1.136 -0.250 
3 0.183 0.138 0.194 -0.099 0.466 
4 -0.543(*) 0.253 0.040 -1.061 -0.026 
5 -0.423 0.259 0.113 -0.953 0.107 
2 
6 -0.403 0.232 0.093 -0.879 0.072 
1 -0.877(*) 0.208 0.000 -1.301 -0.452 
2 -0.183 0.138 0.194 -0.466 0.099 
4 -0.727(*) 0.217 0.002 -1.170 -0.283 
5 -.0607(*) 0.239 0.017 -1.096 -0.117 
3 
6 -0.587(*) 0.233 0.018 -1.064 -0.109 
1 -0.150 0.192 0.440 -0.542 0.242 
2 0.543(*) 0.253 0.040 0.026 1.061 
3 0.727(*) 0.217 0.002 0.283 1.170 
5 0.120 0.199 0.550 -0.286 0.526 
4 
6 0.140 0.195 0.478 -0.258 0.538 
1 -0.270 0.155 0.091 -0.586 0.046 
2 0.423 0.259 0.113 -0.107 0.953 
3 0.607(*) 0.239 0.017 0.117 1.096 
4 -0.120 0.199 0.550 -0.526 0.286 
5 
6 0.020 0.154 0.898 -0.295 0.335 
1 -0.290 0.188 0.133 -0.674 0.094 
2 0.403 0.232 0.093 -0.072 0.879 
3 0.587(*) 0.233 0.018 0.109 1.064 
4 -0.140 0.195 0.478 -0.538 0.258 
6 
5 -0.020 0.154 0.898 -0.335 0.295 
Based on estimated marginal means  
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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From the table above, it can be seen that there was a significant difference in the mean 
average daily pain score between the periods when participants were on no medication 
(Weeks 1 and 4) and those when they were on CoQ10 (Weeks 2 and 3); p<0.05.  It is 
also noted that the mean average daily pain scores of the no medication periods (Weeks 
1 and 4) and placebo period (Weeks 5 and 6) did not differ significantly, with p>0.05. 
 
Further thorough testing using t-paired analysis performed to determine whether there 
were any differences in the average pain score associated with the muscle cramps 
between two medication periods, namely the periods when participants were on CoQ10 
(Weeks 2 + 3) and those when they were on placebo (Weeks 5 + 6). From t-paired 
analysis, on average, participants experienced significantly lower average pain scores 
during the periods they were on CoQ10 (Weeks 2 + 3; mean score= 6.36 ± 0.75), than 
on placebo (Weeks 5 + 6; mean score= 7.37 ± 0.85), with t (29) = - 2.316; 95% CI= -
1.902 –  -0.118; p= 0.028. 
 
 
 
4.2.5.3.2 Group B –non-statin users (Controls) 
Table 4.27 below presents the mean of average pain scores associated with the muscle 
cramps from each patient in the Group B across the 6 weeks of the study. 
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Table 4.27 Group B – Mean of average pain scores per week 
 
Mean of average daily pain score per week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline Placebo Washout CoQ10 
1 2.2 3.3 3.5 3.5 2.0 2.7 
2 2.0 1.5 1.0 1.0 1.5 2.0 
3 2.4 2.0 3.0 3.0 1.0 2.0 
4 3.0 4.0 4.0 3.5 6.0 6.5 
5 2.0 2.0 1.0 2.0 1.0 0 
6 3.0 2.0 2.0 3.0 2.0 3.0 
7 4.0 4.0 3.0 4.0 4.0 3.0 
8 6.0 6.5 8.0 7.0 7.0 8.0 
9 1.0 0 0 1.0 1.0 0 
10 2.0 2.2 1.8 2.2 1.7 1.7 
11 5.5 4.5 5.0 5.0 4.0 4.0 
12 5.7 4.8 4.3 5.5 4.3 4.0 
13 4.0 3.3 3.0 3.3 2.8 2.5 
14 3.0 2.8 3.0 3.0 2.5 2.5 
15 5.0 2.0 2.0 4.0 3.0 0 
16 3.1 3.8 2.7 2.4 2.7 2.3 
17 4.5 3.8 4.5 5.0 4.3 4.0 
18 2.8 1.5 1.0 2.0 2.0 2.0 
19 3.8 3.0 2.5 3.4 2.5 2.7 
20 4.0 4.5 5.0 5.0 5.0 6.0 
21 5.4 5.0 4.8 5.3 5.0 4.5 
22 8.2 7.0 7.0 8.1 7.0 8.0 
23 7.2 8.0 9.0 7.0 7.5 8.0 
MEAN 3.9 3.5 3.5 3.9 3.5 3.4 
SD 1.8 1.9 2.2 1.9 2.0 2.4 
 
In general, the mean of the mean average daily pain scores per week was lowest when 
participants were on either placebo (Weeks 2 and 3) or CoQ10 100 mg daily (Weeks 5 
and 6), and highest when they were on no medication, namely the baseline period (Week 
1) and the wash out period (Week 4).  
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It is found while eight of 23 participants (34.8%) noted their pain scores were lower 
when they were on placebo, 14 of them (60.1%) pointed out they had minimal pain score 
with CoQ10. One participant (4.4%) was noted not experiencing any differences in their 
average pain score with both CoQ10 and placebo.   
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the average pain score associated with the muscle cramps in the 
Group B over the 6-week period of time.  The data were found to have violated the 
sphericity assumption (the variances across the weeks were not equal), thus Greenhouse-
Geisser correction was then used to provide a valid F-ratio. The results show that the 
average pain score was not significantly different over 6 weeks period of time, F (2.349, 
51.681) = 1.909, p= 0.152 (using Greenhouse-Geisser correction). The interpretation of 
the results (Scheffè test) was discontinued because the main effects were non-
significant. 
 
Further t-paired analysis was undertaken to determine whether there were any 
differences in the mean average daily pain scores between the two medication periods, 
namely the periods when participants were on CoQ10 (Weeks 5 + 6) and those when 
they were on placebo (Weeks 2 + 3).  It was found that, on average, participants 
experienced a higher average pain scores during the periods they were on placebo 
(Weeks 2 + 3; mean score= 7.07 ± 0.86), than on CoQ10 (Weeks 5 + 6; mean score= 
6.92 ± 0.91). However, this difference was not statistically significant (t (22) = 0.463; 
(95% CI= -0.514 – 0.809; p= 0.648). 
 
 
 
4.2.5.4. Maximum Pain Score Associated with the Muscle Cramps 
4.2.5.4.1 Group A - Statin Group  
Table 4.28 below shows the mean of maximum pain scores associated with the muscle 
cramps from each statin user over the 6 weeks of the study. 
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Table 4.28 Group A – Mean of maximum pain score per week 
Mean of maximum pain score per week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline CoQ10 Washout Placebo 
1 7.2 6.8 7.0 7.0 7.3 7.3 
2 5.0 5.0 7 7.0 6.0 5.0 
3 2.7 2.3 1.2 1.5 1.4 2.7 
4 3.0 0 1.0 2.0 3.0 2.0 
5 2.9 1.6 2.6 2.2 2.4 1.9 
6 1.0 2.0 1.0 1.0 1.0 1.0 
7 2.0 1.0 1.0 2.0 2.0 2.0 
8 3.0 3.0 2.5 2.0 0 0 
9 3.5 3.3 3.2 3.0 4.1 3.8 
10 5.0 4.0 4.0 5.0 5.7 6.0 
11 3.6 2.8 2.5 3.3 3.4 2.9 
12 4.0 6.0 6.0 4.0 3.0 3.0 
13 2.0 0 0 3.0 0 1.0 
14 2.0 1.5 0 2.0 2.0 1.5 
15 6.5 6.0 6.0 6.0 5.0 5.0 
16 7.0 6.0 5.0 6.0 8.0 7.0 
17 9.0 8.0 8.0 10.0 9.0 9.0 
18 1.0 0 1.0 2.0 1.0 1.0 
19 7.0 5.0 4.5 5.0 6.0 7.0 
20 6.0 4.0 4.0 5.0 4.0 5.0 
21 0 0 0 1.0 0 2.0 
22 4.0 3.0 3.0 4.0 4.0 4.0 
23 2.0 2.0 2.0 4.0 3.0 3.0 
24 8.5 6.0 5.5 7.5 8.0 7.0 
25 3.0 4.0 3.0 4.0 3.0 2.0 
26 5.0 4.0 4.0 4.2 4.0 5.2 
27 7.0 7.0 6.0 8.0 8.0 8.0 
28 4.0 3.0 3.0 6.0 5.0 5.0 
29 4.0 5.0 5.0 3.0 3.0 3.0 
30 5.5 3.0 3.0 4.5 5.0 5.3 
MEAN 4.2 3.5 3.4 4.2 3.9 4.0 
SD 2.3 2.2 2.2 2.3 2.5 2.4 
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As an overall trend, the mean of the maximum pain scores per week that was associated 
with the muscle cramps was highest when participants was on no medication, namely 
the baseline period (Week 1) and the wash out period (Week 4), and lowest when they 
were on CoQ10 100 mg (Weeks 2 and 3). On average, participants experienced a higher 
maximum pain score when they were on placebo (Weeks 5 and 6) than on CoQ10, but 
lower than when they were on the baseline and the washout periods. 
 
Of the 30 participants in the Group A, 20 (66.7%) showed positive responses to CoQ10 
(i.e. they had lower maximum pain score associated with the muscle cramps), while the 
rest of them (33.3%) showed positive responses to placebo.   
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the maximum pain scores associated with muscle cramps in the 
Group A over the 6-week period.  The data were found to have violated the sphericity 
assumption (the variances across the weeks were not equal), thus Greenhouse-Geisser 
correction was then used to provide a valid F-ratio97. The results show that the maximum 
pain score was significantly different over the weeks of treatment, F (2.767, 80.234) = 
5.033, p= 0.004 (using Greenhouse-Geisser correction). 
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the maximum pain score associated with the muscle cramps between the Weeks of 
study (Table 4.29).   
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Table 4.29 Group A- Significant Inter-Week Differences in Maximum Pain Score 
as Identified by Scheffè testing  
 
95% Confidence Interval for 
Difference(a) (I) 
Week 
(J) 
Week 
Mean Difference 
(I-J) 
 
SE 
 
P value (a)
 
Lower Bound Upper Bound
2 0.703(*) 0.206 0.002 0.282 1.124 
3 0.813(*) 0.219 0.001 0.365 1.262 
4 0.040 0.192 0.837 -0.353 0.433 
5 0.303 0.182 0.106 -0.069 0.676 
1 
6 0.260 0.177 0.154 -0.103 0.623 
1 -0.703(*) 0.206 0.002 -1.124 -0.282 
3 0.110 0.131 0.409 -0.158 0.378 
4 -0.663(*) 0.232 0.008 -1.139 -0.188 
5 -0.400 0.261 0.136 -0.933 0.133 
2 
6 -0.443 0.262 0.101 -0.979 0.092 
1 -0.813(*) 0.219 0.001 -1.262 -0.365 
2 -0.110 0.131 0.409 -0.378 0.158 
4 -0.773(*) 0.216 0.001 -1.216 -0.331 
5 -0.510 0.262 0.061 -1.045 0.025 
3 
6 -0.553 0.271 0.050 -1.108 0.001 
1 -0.040 0.192 0.837 -0.433 0.353 
2 0.663(*) 0.232 0.008 0.188 1.139 
3 0.773(*) 0.216 0.001 0.331 1.216 
5 0.263 0.184 0.162 -0.112 0.639 
4 
6 0.220 0.192 0.261 -0.173 0.613 
1 -0.303 0.182 0.106 -0.676 0.069 
2 0.400 0.261 0.136 -0.133 0.933 
3 0.510 0.262 0.061 -0.025 1.045 
4 -0.263 0.184 0.162 -0.639 0.112 
5 
6 -0.043 0.136 0.752 -0.322 0.235 
1 -0.260 0.177 0.154 -0.623 0.103 
2 0.443 0.262 0.101 -0.092 0.979 
3 0.553 0.271 0.050 -0.001 1.108 
4 -0.220 0.192 0.261 -0.613 0.173 
6 
5 0.043 0.136 0.752 -0.235 0.322 
Based on estimated marginal means  
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffè test showed there was a significant difference in the maximum pain score 
associated with muscle cramps during the time when participants were on no medication 
(Weeks 1 and 4) and on CoQ10 (Weeks 2 and 3), with p<0.05. 
 
Further analysis using t-paired analysis was performed to determine whether there were 
any differences in the maximum pain score associated with the muscle cramps between 
two medication periods, namely the periods when participants were on CoQ10 (Weeks 2 
+ 3) and those when they were on placebo (Weeks 5 + 6). This revealed that on average, 
participants experienced a lower maximum pain score during the periods they were on 
CoQ10 (Weeks 2 + 3; mean score= 6.91 ± 0.81) than on placebo (Weeks 5 + 6; mean 
score= 7.86 ± 0.89). However, the difference was not significant (t (29) = -1.935; (95% 
CI= -1.961 – 0.054; p= 0.063). 
 
 
4.2.5.4.2 Group B – non-statin users (Controls) 
Table 4.30 below shows the mean of the maximum pain score associated with the 
muscle cramps from each patient in the Group B over the 6 weeks of the study. 
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Table 4.30 Group B – Mean of maximum pain score per week   
Mean of maximum pain score per week 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline Placebo Washout CoQ10 
1 2.5 3.3 3.5 3.5 2.0 3.0 
2 2.3 1.5 1.0 1.0 1.5 2.0 
3 2.4 2.0 3.0 3.0 1.0 2.0 
4 4.0 3.0 2.0 3.3 4.0 5.0 
5 2.0 2.0 1.0 2.0 1.0 0 
6 3.0 2.0 2.0 3.0 2.0 3.0 
7 5.0 4.0 4.0 5.0 4.0 4.0 
8 7.0 7.5 8.5 8.0 8.0 8.5 
9 1.0 0 0 1.0 1.0 0 
10 2.8 2.5 2.0 2.5 2.0 2.0 
11 5.5 4.5 5.0 5.0 4.0 4.0 
12 6.8 6.0 5.0 5.0 5.3 4.8 
13 4.5 4.3 4.0 4.3 4.0 3.3 
14 3.5 2.8 3.3 3.0 2.5 2.5 
15 5.0 3.0 2.0 5.0 3.0 0 
16 3.7 4.1 3.5 2.8 3.3 2.8 
17 4.8 4.3 4.5 5.3 4.5 4.0 
18 2.8 1.5 1.5 2.0 2.0 1.8 
19 4.0 3.0 4.0 5.0 3.0 3.0 
20 4.0 5.5 6.0 6.0 6.0 7.0 
21 7.1 7.0 6.0 7.0 6.0 5.5 
22 8.5 7.5 7.0 8.4 8.5 9.0 
23 7.8 8.0 9.0 7.5 8.0 8.5 
MEAN 4.4 3.9 3.8 4.3 3.8 3.7 
SD 2.0 2.2 2.4 2.1 2.3 2.6 
 
As an overall trend, the mean of the maximum pain score per week associated with the 
muscle cramps was highest when participants were on no medication, namely the 
baseline period (Week 1) and the wash out period (Week 4), and lowest when they were 
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on CoQ10 100 mg daily (Weeks 5 and 6). On average, participants experienced slightly 
higher maximum pain scores when they were on placebo (Weeks 2 and 3) than on 
CoQ10, but lower than when they were on the baseline and the washout periods. 
 
Of the 23 participants in the Group B, the majority of participants (52.2%; 12 of 23 
participants) showed positive responses to CoQ10 (i.e. they had lower maximum pain 
score associated with the muscle cramps). In contrast, 10 of the participants (43.5%) had 
positive responses with placebo, and one person (4.4%) did not show positive responses 
with both CoQ10 and placebo.   
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the maximum pain score associated with the muscle cramps in 
the Group B over the 6-week period. The data were found to have violated the sphericity 
assumption (the variances across the weeks were not equal), thus Greenhouse-Geisser 
correction was then used to provide a valid F-ratio97. The results show that the maximum 
pain score was significantly different over the weeks of treatment, F (2.719, 59.822) = 
3.429, p= 0.026 (using Greenhouse-Geisser correction).   
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the maximum pain score associated with the muscle cramps between the Weeks of 
study (Table 4.31).   
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Table 4.31 Group B- Significant Inter-Week Differences in Maximum Pain Score 
as Identified by Scheffè testing 
  
95% Confidence Interval for Difference(a)(I) 
Week 
(J) 
Week 
Mean Difference 
(I-J) 
 
SE 
 
p value (a) 
 
Lower Bound Upper Bound 
2 0.465(*) 0.163 0.009 0.128 0.802 
3 0.530(*) 0.247 0.043 0.017 1.043 
4 0.061 0.173 0.728 -0.298 0.420 
5 0.583(*) 0.181 0.004 0.207 0.958 
1 
6 0.622 0.317 0.063 -0.036 1.280 
1 -0.465(*) 0.163 0.009 -0.802 -0.128 
3 0.065 0.147 0.662 -0.240 0.370 
4 -0.404(*) 0.169 0.026 -0.754 -0.054 
5 0.117 0.140 0.412 -0.174 0.409 
2 
6 0.157 0.246 0.532 -0.354 0.667 
1 -0.530(*) 0.247 0.043 -1.043 -0.017 
2 -0.065 0.147 0.662 -0.370 0.240 
4 -0.470(*) 0.188 0.020 -0.860 -0.080 
5 0.052 0.194 0.790 -0.349 0.454 
3 
6 0.091 0.229 0.694 -0.384 0.566 
1 -0.061 0.173 0.728 -0.420 0.298 
2 0.404(*) 0.169 0.026 0.054 0.754 
3 0.470(*) 0.188 0.020 0.080 0.860 
5 0.522(*) 0.175 0.007 0.158 0.885 
4 
6 0.561 0.288 0.065 -0.037 1.159 
1 -0.583(*) 0.181 0.004 -0.958 -0.207 
2 -0.117 0.140 0.412 -0.409 0.174 
3 -0.052 0.194 0.790 -0.454 0.349 
4 -0.522(*) 0.175 0.007 -0.885 -0.158 
5 
6 0.039 0.191 0.840 -0.357 0.436 
1 -0.622 0.317 0.063 -1.280 0.036 
2 -0.157 0.246 0.532 -0.667 0.354 
3 -0.091 0.229 0.694 -0.566 0.384 
4 -0.561 0.288 0.065 -1.159 0.037 
6 
5 -0.039 0.191 0.840 -0.436 0.357 
Based on estimated marginal means  
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffè test showed there was a significant difference in the maximum pain score 
associated with muscle cramps during the time when participants were on no medication 
(Weeks 1 and 4) and on CoQ10 (Week 5), and on placebo (Weeks 2 and 3), with p<0.05   
 
 
Further thorough test using t-paired analysis, was performed to determine whether there 
were any differences in the maximum pain score associated with the muscle cramps 
between the two medication periods, namely the periods when participants were on 
CoQ10 (Weeks 5 + 6) and those when they were on placebo (Weeks 2 + 3). From t-
paired analysis, on average, participants in the Group B had a higher maximum pain 
score during the periods they were on placebo (Weeks 2 + 3; mean score= 7.70 ± 0.93), 
than on CoQ10 (Weeks 5 + 6; mean score= 7.49 ± 1.00). However, the difference was 
not significant (t (22) = 0.623; 95% CI= -0.486 – 0.903; p= 0.540).  
 
 
 
 
4.2.5.5 THE DURATION OF THE CRAMPS 
4.2.5.5.1 Group A - Statin Group 
Table 4.32 below shows the duration of the cramps per week suffered by each statin user 
over the 6 weeks of the study.  
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Table 4.32 Group A – Average of Cramp Duration per Week (minutes) 
Average of cramps duration per week (minutes) 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline CoQ10 Washout Placebo 
1 0.8 0.9 0.9 1.0 1.2 0.9 
2 3.6 3.8 4.8 5.0 5.0 4.5 
3 2.3 1.7 1.3 2.0 2.0 2.1 
4 2.0 0 1.5 1.5 1.5 1.3 
5 7.5 7.0 6.5 5.0 5.0 5.5 
6 2.0 1.0 1.0 1.0 1.0 1.0 
7 2.0 1.0 1.0 3.0 3.0 3.0 
8 1.1 1.5 1.3 1.7 0 0 
9 0.4 0.2 0.1 0.1 0.2 0.3 
10 10.0 9.5 9.0 10 10.0 10 
11 1.0 1.3 1.0 1.2 2.3 1.5 
12 0.8 0.6 0.5 0.8 0.8 1.0 
13 0.5 0 0 0.3 0 0.3 
14 0.5 0.5 0 0.5 0.3 0.3 
15 3.5 2.9 2.7 3.2 3.4 3.5 
16 5.3 3.8 3.8 4.0 3.8 4.3 
17 5.7 4.3 4.5 5.0 5.5 5.3 
18 2.3 0 1.8 1.7 2.1 2.0 
19 4.5 4.2 3.8 4.0 3.5 3.7 
20 2.2 2.0 1.8 2.0 2.2 2.0 
21 0 0 0 1.0 0 1.5 
22 2.2 1.8 1.5 2.7 2.4 2.1 
23 1.8 1.0 0.8 2.0 1.7 1.4 
24 9.0 7.5 8.0 7.5 8.0 8.0 
25 2.0 1.5 1.0 2.0 2.5 2.7 
26 3.5 2.2 2.0 2.8 3.7 3.5 
27 5.0 3.8 4.5 4.5 5.2 6.0 
28 2.8 3.3 2.9 4.0 2.9 3.5 
29 2.2 2.8 2.0 3.5 3.0 3.2 
30 4.3 3.3 3.1 4.8 4.5 4.0 
MEAN 3.0 2.4 2.4 2.9 2.9 2.9 
SD 2.5 2.3 2.3 2.2 2.3 2.3 
 
 
In general, the average of cramp duration per week was longest when participants were 
on no medication, namely the baseline period (Week 1) and the wash out period (Week 
4), and shortest when they were on CoQ10 100 mg daily (Weeks 2 and 3). On average, 
participants experienced longer cramp duration when they were on placebo (Weeks 5 
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and 6) than on CoQ10, but shorter than during the baseline (Week 1). There were no 
differences between the mean cramp duration during Week 4 (washout), and Weeks 5 
and 6 (placebo). 
 
Of the 30 participants in the Group A, the majority (26; 86.7%) of participants 
experienced shorter duration of cramps with CoQ10; whereas three participants (10%) 
had shorter cramp duration with placebo. The remaining participant did not experience 
any difference in the cramps duration with either CoQ10 or placebo.   
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in the cramp duration of the Group A over the 6-week period of 
time. The data were found to have violated the sphericity assumption (the variances 
across the weeks were not equal), thus Greenhouse-Geisser correction was then used to 
provide a valid F-ratio97. The results show that the cramps duration was significantly 
different over the weeks of treatment, F (3.110, 90.188) = 8.131, p= 000 (using 
Greenhouse-Geisser correction). 
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the cramps duration between the Weeks of study (Table 4.33).   
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Table 4.33 Group A- Significant Inter-Week Differences in Cramp Duration as 
Identified by Scheffè testing 
95% Confidence Interval for 
Difference(a) (I)  
Week 
(J)  
Week 
Mean Difference 
(I-J) 
 
SE 
 
p value 
(a) 
 Lower Bound Upper Bound 
2 0.580(*) 0.133 0.000 0.308 0.852 
3 0.590(*) .0106 0.000 0.374 0.806 
4 0.100 .0157 0.529 -0.221 0.421 
5 0.137 .0147 0.360 -0.164 0.437 
1 
6 0.080 .0140 0.573 -0.207 0.367 
1 -0.580(*) .0133 0.000 -0.852 -0.308 
3 0.010 .0106 0.926 -0.207 0.227 
4 -0.480(*) .0136 0.001 -0.757 -0.203 
5 -0.443(*) .0167 0.013 -0.784 -0.103 
2 
6 -0.500(*) .0156 0.003 -0.819 -0.181 
1 -0.590(*) .0106 0.000 -0.806 -0.374 
2 -0.010 .0106 0.926 -0.227 0.207 
4 -0.490(*) .0127 0.001 -0.749 -0.231 
5 -0.453(*) .0141 0.003 -0.742 -0.165 
3 
6 -0.510(*) .0135 0.001 -0.787 -0.233 
1 -0.100 .0157 0.529 -0.421 0.221 
2 0.480(*) .0136 0.001 0.203 0.757 
3 0.490(*) .0127 0.001 0.231 0.749 
5 0.037 .0105 0.729 -0.178 0.251 
4 
6 -0.020 .0105 0.850 -0.234 0.194 
1 -.0137 .0147 0.360 -0.437 0.164 
2 0.443(*) .0167 0.013 0.103 0.784 
3 0.453(*) .0141 0.003 0.165 0.742 
4 -0.037 .0105 0.729 -0.251 0.178 
5 
6 -0.057 .0080 0.482 -0.219 0.106 
1 -0.080 .0140 0.573 -0.367 0.207 
2 0.500(*) .0156 0.003 0.181 0.819 
3 0.510(*) .0135 0.001 0.233 0.787 
4 0.020 .0105 0.850 -0.194 0.234 
6 
5 0.057 .0080 0.482 -0.106 0.219 
Based on estimated marginal means  
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffe analysis revealed that cramp duration whilst the participants were on 
CoQ10 (Week 2 and 3) was significantly shorter and than during any other period of the 
study, such as Weeks 1, 4, 5 and 6.   
 
Further thorough testing using t-paired analysis was undertaken to determine whether 
there were any significant differences in the cramp durations between the two 
medication periods, namely the periods when participants were on CoQ10 (Weeks 2 + 
3) and those when they were on placebo (Weeks 5 + 6). From t-paired analysis, on 
average, participants experienced significantly shorter cramps durations during the 
periods they were on CoQ10 (Weeks 2 + 3; mean score= 4.88 ± 0.84 minutes), than on 
placebo (Weeks 5 + 6; mean score= 5.84 ± 0.85 minutes) with t (29) = - 3.535; 95% CI= 
-1.505 – -0.402; p= 0.001.   
 
 
 
 
4.2.5.5.2 Group B – non-statin users (Controls) 
Table 4.34 below shows the duration of the cramps per week suffered by each 
participant in the Group B over the 6 weeks of the study. 
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Table 4.34 Group B – Average of Cramp Duration Per Week (minutes) 
Average of cramps duration per week (minutes) 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Patient 
No Baseline Placebo Washout CoQ10 
1 2.2 2.0 3.5 4.0 3.8 2.5 
2 0.5 0.3 0.3 0.3 0.3 0.2 
3 2.3 2.3 1.7 1.5 1.5 1.0 
4 2.2 3.3 2.0 3.8 3.0 3.0 
5 0.2 0.2 0.1 0.1 0.1 0 
6 3.0 2.0 2.0 3.0 2.0 1.0 
7 3.0 3.0 2.5 3.0 2.8 2.3 
8 1.7 1.6 1.5 1.3 1.5 1.4 
9 1.3 0 0 1.3 1.0 0 
10 1.3 1.0 0.8 1.2 0.5 0.5 
11 7.0 6.0 7.5 6.0 5.0 5.0 
12 2.8 1.8 2.0 2.3 2.0 2.0 
13 4.3 3.8 3.5 4.5 4.0 4.0 
14 2.7 2.5 2.3 3.0 2.0 2.8 
15 1.0 0.5 0.8 1.0 0.5 0 
16 2.0 1.3 1.0 2.0 1.4 1.0 
17 4.2 3.7 4.0 4.5 3.7 4.0 
18 2.3 1.5 2.3 2.3 2.0 1.5 
19 10.0 9.3 9.5 11.0 10.0 8.0 
20 5.0 4.3 3.5 4.5 4.0 5.0 
21 5.8 4.9 5.0 5.3 5.1 4.7 
22 9.5 8.8 8.3 8.0 7.5 8.8 
23 9.4 9.2 8.8 8.5 7.5 8.7 
MEAN 3.6 3.2 3.2 3.6 3.1 2.9 
SD 2.9 2.8 2.8 2.8 2.6 2.7 
 
 
In general, the average of cramp duration per week was longest when participants were 
on no medication, namely the baseline period (Week 1) and the wash out period (Week 
4), and shortest when they were on CoQ10 100 mg daily (Weeks 5 and 6). On average, 
participants experienced shorter duration of cramps when they were on placebo (Weeks 
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2 and 3) than on the baseline and washout periods, but slightly longer than when they 
were on CoQ10. 
 
 
Amongst the 23 participants in the Group B, more than half (13; 56.5%) experienced 
shorter cramp duration with CoQ10, while seven (30.4%) of the participants had shorter 
cramp duration with placebo. The remaining three participants did not experience any 
differences in the cramp duration with either CoQ10 or placebo.   
 
 
Repeated measures ANOVA analysis was performed to determine whether or not there 
were any differences in cramp duration of the Group B over the 6-week period.  The 
data were found to have violated the sphericity assumption (the variances across the 
weeks were not equal), thus Greenhouse-Geisser correction was then used to provide a 
valid F-ratio97. The results than show that the cramps duration was significantly different 
over the weeks of treatment, F (3.279, 72.142) = 7.507, p= 0.000 (using Greenhouse-
Geisser correction). 
 
 
 
Scheffè testing was then undertaken to determine where significant differences existed 
in the cramp duration between the Weeks of study (see table 4.35).   
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Table 4.35 Group B- Significant Inter-Week Differences in Cramp Duration as 
Identified by Scheffè testing 
  
95% Confidence Interval for 
Difference (a) (I)  
Week (J) Week  
 
Mean Difference 
(I-J) 
 
SE 
 
p value (a) 
 Lower Bound Upper Bound 
2 0.452(*) 0.105 0.000 0.234 0.671 
3 0.470(*) 0.126 0.001 0.209 0.730 
4 0.057 0.158 0.724 -0.271 0.384 
5 0.543(*) 0.167 0.004 0.196 0.891 
1 
6 0.708(*) 0.151 0.000 0.395 1.021 
1 -0.452(*) 0.105 0.000 -0.671 -0.234 
3 0.017 0.134 0.898 -0.260 0.294 
4 -0.396(*) 0.150 0.015 -0.706 -0.085 
5 0.091 0.153 0.557 -0.226 0.409 
2 
6 0.256(*) 0.113 0.033 0.022 0.490 
1 -0.470(*) 0.126 0.001 -0.730 -0.209 
2 -0.017 0.134 0.898 -0.294 0.260 
4 -0.413(*) 0.150 0.012 -0.724 -0.102 
5 0.074 0.154 0.637 -0.246 0.394 
3 
6 0.239 0.173 0.183 -0.121 0.598 
1 -0.057 0.158 0.724 -0.384 0.271 
2 0.396(*) 0.150 0.015 0.085 0.706 
3 0.413(*) 0.150 0.012 0.102 0.724 
5 0.487(*) 0.078 0.000 0.324 0.649 
4 
6 0.652(*) 0.170 0.001 0.299 1.004 
1 -0.543(*) 0.167 0.004 -0.891 -0.196 
2 -0.091 0.153 0.557 -0.409 0.226 
3 -0.074 0.154 0.637 -0.394 0.246 
4 -0.487(*) 0.078 0.000 -0.649 -0.324 
5 
6 0.165 0.162 0.320 -0.171 0.501 
1 -0.708(*) 0.151 0.000 -1.021 0-.395 
2 -0.256(*) 0.113 0.033 -0.490 0-.022 
3 -0.239 0.173 0.183 -0.5980 0.121 
4 -0.652(*) 0.170 0.001 -1.004 -0.299 
6 
5 -0.165 0.162 0.320 -0.501 0.171 
Based on estimated marginal means  
* The mean difference is significant at the .05 level. 
A Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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The Scheffe analysis demonstrated significant differences in the cramp duration during 
the periods when participants were on placebo (Weeks 2 and 3) and CoQ10 (Weeks 5 
and 6) compared those when they were not receiving any medication (Week 1 and 4), 
with p<0.05. The analysis also revealed that the duration of cramps in Week 6 (the 
second week of CoQ10 period) was significantly shorter than during Week 2 (the first 
week of placebo period), with p<0.05. 
 
Further testing using t-paired analysis, was undertaken to determine whether there were 
any differences in the cramp duration between the two medication periods, namely the 
periods when participants were on CoQ10 (Weeks 5 + 6) and those when they were on 
placebo (Weeks 2 + 3). From t-paired analysis, on average, participants experienced 
longer cramp duration during the periods they were on placebo (Weeks 2 + 3; mean 
score= 6.36 ± 1.16 minutes), than on CoQ10 (Weeks 5 + 6; mean score= 6.03 ± 1.09 
minutes). However, the difference was not statistically significant, with t (22) = 1.539; 
95% CI= -0.115 – 0.775; p= 0.138. 
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CHAPTER FIVE 
DISCUSSION 
 
 
5.1 MUSCLE ADVERSE EFFECT SURVEY 
5.1.1 Patient Demographics 
The Muscle Adverse Effects Survey was conducted from January 2006 to April 2006 in 
45 community pharmacies throughout Western Australia.  A follow up, which was done 
by a second mailing of the questionnaires as well as a reminder letter to the pharmacies, 
was issued to improve the response rate of the questionnaire. However, the response rate 
achieved was still quite low at 38.7% or 356 of a total 920 statin users who enrolled in 
the study. This low response rate might have resulted from the anonymity of participants 
in the survey, which led to difficulties in tracking down the respondents. Furthermore, 
pharmacists reported that many of the statin users had a perception that they did not need 
to return the questionnaire if they did not have muscle symptoms.  
 
Of the 356 participants who returned the questionnaire, 205 of them (111 men and 94 
women) suffered from muscle symptoms. It was found that the respondents who 
reported muscle symptoms (mean age 64.2 years) were significantly older than the rest 
of respondents who reported not having muscle symptoms (mean age 59.2 years). 
Contrary to general opinion24, it was reported that women were not most likely to suffer 
from muscle symptoms. The survey revealed that there was no significant association 
between the sex of statin users and whether or not they had muscle symptoms.    
 
It was also found that besides hypercholesterolaemia, participants suffered from a few 
other diseases. Hypertension was reported to be the most commonly suffered disease, 
comprising 39.93% of total participants, followed by diabetes mellitus (18.3%), 
ischaemic heart disease (11.5%), hypothyroidism (10.1%), and heart failure (3.9%). 
Kidney failure was reported as the least commonly suffered diseases, making up only 
1.4% of total participants. It is worth noting that hypothyroidism can be associated 
directly with myopathy. Research has shown that 20%-50% of hypothyroid patients 
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complain of muscle pain or cramps98. The lack of thyroid hormone may result in 
decreased protein turnover and impaired carbohydrate metabolism, and leads to a shift in 
distribution of muscle fibers and the inhibition of the main oxidative pathways. All these 
factors can manifest as muscle weakness, muscle aching, cramps, fatigue and increased 
CK levels13, 98.   
 
Of the 356 participants, 220 (61.8%) took a few drugs that might be associated with 
myopathy when they were on statin therapy. Alcohol (more than 2 drinks daily) was 
reported as the most common drug taken, accounting for 95 cases or 26.7% of total 
respondents.  The use of alcohol may be associated directly with myopathy. Alcoholic 
skeletal myopathy can be sub-divided into two different forms, acute and chronic 
conditions. Acute alcoholic myopathy is a rare condition affecting approximately 1% of 
alcoholics and is characterized by myalgia, muscle weakness, high levels of CK, renal 
impairment with myoglobinuria, and rhabdomyolysis. Chronic alcoholic myopathy 
(ingestion over 100 mg/day for more than 10 years) occurs in 45% to 70% of alcoholics, 
which leads to progressive proximal weakness and muscle atrophy involving legs and 
arms, and is characterized by reduced muscle strength, and normal or slightly increased 
levels of CK. The aetiology of alcoholic myopathy is multifactorial, including protein 
content disturbances related to the possible role of acetaldehyde, decreases in both 
amino acid availability and insulin-like growth factor concentrations, and free radical-
induced protein membrane damage52, 99-101.  
 
5.1.2 Statin Therapy Used 
The survey showed that most participants had been taking a statin for over 1 year (310; 
84.6%), with atorvastatin being the most commonly prescribed statin (59.3%), followed 
by simvastatin (29.8%), then pravastatin and fluvastatin accounting for 10.4% and 0.6% 
respectively. These findings were similar to Mant et al’s report102,  which revealed that 
atorvastatin was the most prescribed statin in Australia, followed by simvastatin, 
pravastatin and fluvastatin. Table 4.1 shows further details of statin therapy used in 
Australia between 1999 and 2004.  
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Table 5.1 Numbers of Statin Prescribed In Australia102. Australian community 
utilization of individual statins and all statins combined, DDDs/1000 population/day, 
yearly from 1999 to 2004. 
 
Year 
Statin 1999 2000 2001 2002 2003 2004 
  Atorvastatin 27.08 39.25 49.86 61.08 72.22 91.87 
  Simvastatin 24.18 29.73 35.36 40.88 46.98 55.29 
  Pravastatin 6.08 7.93 9.68 11.92 13.33 14.48 
  Fluvastatin 0.93 0.74 0.64 0.56 0.49 0.44 
  Cerivastatin 0.54 1.83 1.97 0 0 0 
  All statins 58.8 79.47 97.51 114.44 133.02 162.09 
 
 
The high proportion of atorvastatin users may be due to the fact that atorvastatin may be 
more effective than other statins in treating hypercholesterolaemia24, 103. A study called 
ACCESS (the Atorvastatin Comparative Cholesterol Efficacy and Safety Study) 
involving 3916 patients conducted by Andrews et al104, showed that atorvastatin 
produced a larger decrease in plasma LDL cholesterol than other statins in initial doses. 
In 2005, Australian Government accepted the recommendation of The Pharmaceutical 
Benefits Advisory Committee (PBAC) that Lipitor® (atorvastatin) is more effective at 
lowering cholesterol than other statins, and hence warrants a higher price for PBS 
subsidy. Consequently, Lipitor® was not affected by the 12.5% price reduction affecting 
other brands of cholesterol lowering medication105. 
  
Despite the high use of atorvastatin, the incidence rate of myopathy amongst atorvastatin 
individual users in the survey was found to be similar with fluvastatin, paravastatin and 
simvastatin (it might result from the low number of respondents in the survey). This 
finding is contrary to Rosenson’s hypothesis24, which suggests that statin’s lipophilicity 
in penetrating into peripheral tissues may contribute to an increase in the potential of 
myopathy effects. Rosenson further points out that in vitro and in vivo studies support 
the idea that hydrophilic agents (such as pravastatin) are less likely to produce muscular 
effects than lipophilic agents (such as atorvastatin and simvastatin). However, this 
opinion is opposed by The National Lipid Association’s Muscle Safety Expert Panel49.  
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The panel argues that statins do vary in their myotoxicity, but there are no direct 
comparisons among statins as to their myotoxic potential. 
 
In this study it was found that there was no association between the dose of statin used 
and myopathy. This might be due to the fact that there were small numbers of patients so 
the study was never powered to detect a genuine effect of the dose of statins used and 
their association to myopathy97. 
 
 
5.1.3 Prevalence and Nature of Statin-Induced Myopathy 
By assuming that non-respondents did not suffer from muscle symptoms, it was 
estimated that the prevalence of myopathy from this survey was 22.3% (205/920). 
Amongst the respondents with muscle symptoms, 73 (35.6%) reported their muscle 
symptoms had been worsening on using statins. This reduced the overall incidence of 
statin-induced myopathy to 73/920 or 7.93%. This figure was quite close to the 
prevalence of statin-induced myopathy reported by Thompson et al37. They believed that 
the less serious adverse effects of statins are underreported, and may vary between 1% 
and 5%.   
 
The survey identified that the most commonly experienced muscle symptom amongst 
statin users was night cramps (54.6% of total respondents); while the most commonly 
affected area of the body were the calves (61.9%). It was worth noting that on average 
patients on statins reported suffering 2.5 muscle symptoms.    
 
5.1.4 Factors Increasing the Risk of Statin-Induced Myopathy 
Statistical analysis with Multiple Logistic Regression was performed to determine 
factors increasing the risk of myopathy amongst statin users, with a series of explanatory 
variables including the respondent’s age and sex, statin therapy (fluvastatin data were 
excluded from analysis due to low number of users), duration of statin therapy, other 
diseases suffered (heart failure, heart attack, hypertension, hypothyroid, diabetes 
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mellitus and kidney failure), and other medicines taken (cortisone, prednisone, sodium 
valproate, nifedipine, diltiazem, amiodarone, alcohol, labetolol, and chemotherapy). 
 
It was found that increase in age, experiencing heart failure and taking cortisone-like 
drugs is associated with statin users becoming more susceptible to myopathy. For every 
1-year increase in age, the odds of suffering from myopathy increased 1.039 (95% CI 
1.019 – 1.061).  Older people are more susceptible to myotoxicity due to normal muscle 
loss (atrophy) that begins in the mid-40s, and accelerates with inactivity14.  
 
Furthermore, taking cortisone-like medication increased the odds of suffering myopathy 
16.4 times (95% CI 2.2 – 124.3), while patients with heart failure were 9.4 times (95% 
CI 1.2 – 73.2) more likely to develop muscle symptoms when prescribed statins. 
 
Owczarek et al52 in their review mentions that high doses of corticosteroids may result in 
“Corticosteroid Myopathy”, a condition with loss of the thick myofilament from the 
muscle that manifests in proximal weakness, atrophy, myalgia, increased CK levels and 
rhabdomyolysis.  These conditions result from the impaired regulation of the activity 
factors involved in peptide initiation by corticosteroid, which leads to the inhibition of 
protein synthesis (primarily in type II muscle fibers). Moreover, corticosteroid also 
increases the cyctoplasmic protease activity in muscles, leading to myofibrillar 
destruction.  Glutamine synthetase is an enzyme needed to catalyze the formation of 
glutamine from glutamate and ammonia. The excess of corticosteroid results in the 
decrease of muscle protein synthesis with the reduced intramuscular glutamine levels. 
This leads to the increased glutamine synthetase activity in skeletal muscles that releases 
high levels of glutamine, resulting from the intensified proteolysis process39, 52. 
 
Another risk factor identified was heart failure. Myopathy and heart failure can be 
associated with reduced CoQ10 levels. Jeejeebhoy et al73 point out that the degree of 
CoQ10 reduction is related to the severity of heart failure. CoQ10 content is also 
decreased in aged myocardium, which may contribute to the reduced recovery of 
contractile function in aged myocardium observed after cardiac surgery106. CoQ10 
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functions as an antioxidant and a transmembrane proton conductor and an electron 
carrier between NADH and succinate dehydrogenases and the cytochrome system, 
which is needed for the phosphorylation of ADP into ATP66-71. In patients with heart 
failure, CoQ10 is believed to be able to improve the efficiency of cardiac mitochondrial 
energy production, increase myocardial tolerance to hypoxic stress, and reduce 
intraoperative myocardial damage107. A decline in the CoQ10 levels may contribute to 
impaired muscle function, including myocardium106, 107. As statins inhibit the formation 
of mevalonate, a precursor of CoQ10, statin users with heart failure might become more 
susceptible to myotoxicity. 
 
 
5.2 COENZYME Q10 FOR MUSCLE CRAMPS STUDY 
5.2.1 Patients Demographics 
A total of 53 participants were included in the statistical analysis, 30 people in the Group 
A (stain users) and 23 people in the Group B (non-statin users). It was found that 
participants in the Group A were significantly older than those in the Group B, with 
Mean Difference of 6.17 years (95% CI: 1.02-11.83). More than half of the participants 
(41; 77.4%) had cramps at least once a week, and most of them (38; 71.7%) had been 
suffering from cramps for over 5 years. Furthermore, it was also reported that only 11 of 
53 participants (20.8%) had family history associated with muscle cramps. 
 
In the Group A, alcohol became the most commonly consumed drug besides the statin, 
accounting for 11 cases (22.9%), while in the Group B, magnesium was noted to be the 
most frequently used drug, making up 13 cases (26%). In contrast with participants in 
the Group A, it was reported that none of the participants in the Group B suffered from 
hypercholesterolaemia. The most common disease suffered by participants in both 
groups was hypertension, making up 11 cases (20.8% of total participants). 
 
 5.2.2 Part of the Body Affected by Cramps 
Participants were given a diary to record the following data across the 6 weeks of the 
study: days on which cramps were experienced, number of cramps suffered per day, 
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average and maximum pain score (on a scale of 0 to 10), duration of the cramps (in 
minutes), part(s) of body affected by the cramps, and any adverse reactions suffered over 
the duration of the study.  
 
During the study, it was found that the majority of participants reported their calves as 
the most affected area of the body (34; 64.2% of total participants), followed by legs 
(20; 37.7%), thighs and buttocks (18; 34%) and feet (16; 30.2%). Fingers, on the other 
hand, were reported as the least affected area of the body, only accounting for 1 case 
(1.9% of total participants). This finding is similar to few literatures which mention the 
calf is the most commonly affected area 2, 4, 9 
 
5.2.3 CoQ10 Efficacy 
The efficacy of CoQ10 was assessed on the basis of changes in the following: the 
average number of days per week participants suffered from muscle cramps, the average 
number of muscle cramps suffered per day, the intensity of the pain associated with 
muscle cramps (measured with average and maximum pain score), and the average of 
cramp duration per day.  
 
As an overall trend, most participants in both groups experienced the highest 
improvements (the highest changes) on all assessed variables when they received CoQ10 
100 mg, and experienced the lowest improvements (the smallest changes) when they 
were not on medication, namely the baseline period (Week 1) and the wash out period 
(Week 4). It was worth noting, on average, participants showed higher improvements on 
the assessed variables when they were on placebo than during the baseline and washout 
periods (Weeks 1 and 4), but less than when they were on CoQ10.  
 
“The placebo effects” occurring in this study were considered primarily and 
fundamentally as a psychological phenomenon108-110. There were two main factors that 
might account for the placebo effects; namely anxiety and the expectancy-mediated 
attributes of the therapist-patient relationship108, 111. The placebo effects are often 
attributed to anxiety reduction. Administering of placebo may lead to a decline of 
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anxiety, which may in turn be accompanied by a decrease in the perception of suffering. 
Besides anxiety, the placebo effects may also be mediated by expectancies generated 
within the context of the therapist-patient relationship. The mediation of belief systems 
about the plausibility of treatment and anticipated clinical change were shown in a 
review of double-studies evaluating the effectiveness of a placebo in reducing pain 
compared to other standard analgesic medications108. Placebo has been found to be 56% 
as effective as a standard dose of morphine in reducing clinical postoperative pain in a 
few double-blind studies. Thus, positive response to placebo in this study did not only 
indicate that, for the patients, expectancy and hope for further success in therapy was 
realistic; for the therapist, it indicated that the patients, at some cognitive level, had the 
resources to be able to influence, modulate, and control their pain112, 113.  
 
5.2.3.1 Group A- Statin Users  
In the Group A, more participants experienced higher improvements on all assessed 
variables when they were assigned to CoQ10 100 mg (Weeks 2 and 3) than those who 
showed positive responses with placebo (Weeks 5 and 6), and those who did not 
experience any differences in all assessed variables on either CoQ10 or placebo. It was 
revealed that 63.3% of participants in the Group A experienced fewer days with muscle 
cramps when they were on CoQ10. Furthermore, the proportion of participants in the 
Group A who had a reduction in cramp frequency, average and maximum pain scores 
associated with cramps, and cramp duration when they were on CoQ10 were 66.7%, 
73.3%, 66.7%, and 86.7% respectively. On the other hand, the proportion of participants 
in the Group A who experienced a decrease in days with muscle cramps, cramp 
frequency, average and maximum pain score, and cramp duration during the period on 
placebo were 26.7%, 26.7%, 23.3%, and 33.3%, and 10% respectively.  
 
T-paired test was performed to determine whether or not there were any differences in   
days with muscle cramps, cramp frequency, average and maximum pain score, and 
cramp duration between the two medication periods, namely the periods when they were 
on CoQ10 (Weeks 2 + 3) and those when they were on placebo (Weeks 5 + 6). Despite 
the CoQ10 periods producing higher improvements in all assessed variables than the 
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placebo periods, t-paired test analysis revealed only two data, namely average pain score 
and pain duration, which showed the mean difference between CoQ10 and placebo 
periods were large enough not to be a result of chance chance.  On average, participants 
experienced significantly lower average pain score associated with cramps during the 
CoQ10 period (mean score= 6.36± 0.75) than the placebo period (mean score= 7.37 ± 
0.85; p=0.028). Furthermore, patients also experienced shorter cramp duration during 
periods when they were on CoQ10 (mean score= 4.88 ± 0.84) than those when they were 
on placebo (mean score= 5.84 ± 0.85;  p=0.001). 
 
Therefore, even though therapy with CoQ10 100 mg per day over two weeks did not 
necessarily reduce cramps frequency, exogenous CoQ10 supplementation was shown to 
be effective in reducing pain severity and cramps duration. The supplementation of 
CoQ10 100 mg per day may successfully increase the CoQ10 blood levels, which can be 
reduced due to increased age35, 55, 114, ischaemic heart disease107, 115, 116 and medications 
such as statins.  
 
In terms of age, it was reported that, on average, participants in the Group A were much 
older (64.5±8.4 years) than those in the Group B (58.0±11.3 years). This difference was 
significant, with t(51) = 2.386, p= 0.021. According to Kaikkonen et al114, after 20 years 
of age, CoQ10 levels decline as age increases. Hence, participants in Group A (statin 
users) might have had lower levels of CoQ10 than the controls (Group B), and this 
might make them more susceptible to muscle problems, including muscle cramps.  
Furthermore, CoQ10 levels in the myocardium are also decreased during ischaemia 
reperfusion. Thus, two participants (6.7%) from the Group A might experience CoQ10 
deficiency since they suffered from ischaemia heart disease.  
 
Besides the elderly and people with ischaemia heart disease, low levels of CoQ10 are 
also found in people taking statins. A number of studies have shown that statins reduced 
CoQ10 blood levels54, 57-62. Since CoQ10 and cholesterol have the same biochemical 
pathway, the inhibition of HMG-CoA reductase by statins does not only reduce 
cholesterol levels but also CoQ10 blood levels38. Moreover, CoQ10 is carried by serum 
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lipoproteins in the circulation, and the reduction of cholesterol and triglycerides by 
statins can also lead to reduced concentrations of serum CoQ1055.  
 
These findings support the hypothesis arguing statin-induced myopathy may result from 
the low level of CoQ1038, 48, 52-54. Besides being an essential antioxidant, CoQ10 also 
functions as a transmembrane proton conductor and an electron carrier between NADH 
and succinate dehydrogenases and the cytochrome system which is essential for the 
phosphorylation of ADP into ATP35, 67-69. As muscles need ATP to meet energy 
demands, a decline in the CoQ10 tissues levels may contribute to muscle impairment, 
such as muscle cramps38, 48, 52-54.  
 
Consequently, the consumption of CoQ10 100 mg per day in this trial might have 
prevented the decline and/or increased the CoQ10 levels amongst the statin users; thus, 
reducing the statin-induced muscle adverse effects manifested in muscle cramps. 
 
  
5.2.3.2 Group B- Non Statin Users (Controls) 
In the Group B (non-statin users), more participants experienced higher improvements in 
all assessed variables when they received CoQ10 100 mg daily (Weeks 5 and 6) than 
those who showed positive responses with placebo (Weeks 2 and 3), and those who did 
not experience any differences in all assessed variables on either CoQ10 or placebo.  
 
However, the percentages of participants who showed positive responses to CoQ10 in 
the Group B were slightly lower than those in the Group A. It was revealed 47.8% of 
participants in the Group B experienced fewer days with muscle cramps when they were 
on CoQ10, while 43.5% of them experienced fewer days with muscle cramps when they 
were given placebo. Furthermore, the percentages of participants in the Group B that had 
a reduction in cramp frequency, average and maximum pain score, and the duration of 
the cramps when they were on CoQ10 were 47.8%, 60.1%, 52.2%, and 56.5% 
respectively. In contrast, it was reported that the percentages of participants in the Group 
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B who experienced a decrease in the four the same variables when they were on placebo 
were 39.1%, 34.8%, 43.5%, and 30.4% respectively.  
 
Despite the majority of participants having greater improvements in their muscle cramps 
when they took CoQ10, t-paired analysis confirmed that there were no significant 
differences between CoQ10 and placebo efficacy amongst all assessed variables. This 
may be due to a number of reasons. Firstly, muscle cramps suffered by participants in 
the Group B might not result from CoQ10 deficiency. Ikematsu et al75 argue that 
exogenous CoQ10 supplementation may not affect CoQ10 plasma levels in people who 
do not experience reduced CoQ10 levels. They reported that there were no significant 
differences in CoQ10 plasma concentrations for the 84 volunteers (who did not 
experienced CoQ10 deficiency) after taking CoQ10 at doses 300, 600 and 900 mg/day 
for 4 weeks. Given that participants in the Group B might not take any substance (such 
as statins) or condition that might lower their CoQ10 levels, the administration of 
exogenous CoQ10 supplementation might not affect their CoQ10 levels, and not 
improve the condition of their cramps. 
  
Another factor that might contribute to the lesser efficacy of CoQ10 in Group B was the 
nature of cramps suffered by participants.  It was confirmed that a third of participants in 
the Group B (9 of 23 participants or 39.13%) had a family history of muscle cramps, 
while only two of 30 participants (6.67%) had this in the Group A.  Two participants in 
the Group B are siblings, and they might suffer from a condition described as autosomal-
dominant inherited generalized muscle cramps. Both of them admitted that the cramping 
was first recognized and most severe during adolescence. For these reasons above, 
hypothetically, muscle cramps suffered by participants in the Group B might not be fully 
associated with reduced CoQ10 levels. This may explain why CoQ10 in the Group B 
was not as effective as in the Group A in reducing muscle cramps. Therefore, exogenous 
CoQ10 supplementation may be only effective in reducing muscle cramps associated 
with CoQ10 deficiency, such as in the elderly, ischaemia heart disease patient and also 
statin users.     
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5.2.4 Adverse Events Associated with CoQ10 and Placebo 
The adverse effects of CoQ10 were probably subjective, since there were no significant 
differences in adverse events frequency between CoQ10 and placebo in both Group A 
and Group B. The symptoms were mild and ceased without requiring any treatment; 
they included nausea, stomach upset, insomnia, and flu-like symptoms.    
 
Furthermore, in terms of placebo, it was reported that one participant from the Group B 
experienced a skin rash while taking placebo (on day 5 of the 2nd week of the study), and 
decided to withdraw from the trial. A doctor gave the participant an antihistamine, and 
the Investigator was later informed that since the participant commenced the trial in 
spring, the allergy was most probably caused by pollen, not the medicine (placebo).  
 
 
 5.3 LIMITATIONS OF THE STUDY 
There are several limitations to this study that are important to acknowledge: 
1. The low number of respondents in the Muscle Adverse Effects Survey might have 
resulted in the prevalence of muscle symptoms associated with statin being over-
estimated. On the other hand, the assumption that non-respondents did not suffer 
from muscle symptoms might have resulted in muscle symptoms associated with 
statin being under-estimated. 
2. The low number of respondents in the Muscle Adverse Effects Survey might have 
resulted in no association between the dose of statin used and myopathy, and in 
incidence rate of myopathy amongst individual atorvastatin users to be found similar 
with other statins. 
3. Not all of the data used in the study was retrieved from objective evidence, such as 
the prevalence of respondents reporting their muscle symptoms had worsened on 
using statins. In this case, where data was unavailable from the patient’s medical 
records (such as laboratory test results); patient data was retrieved solely from the 
patient’s questionnaire that may not have been a reliable source. 
4. The study design of the trial conducted was a single-blind study. A double blind 
study is considered as the gold standard for providing a high level of scientific 
validity and reliability. In a single-blind study, there may be some biases that occur 
 98
due to the fact that the investigator is aware of which treatment (either medicine or 
placebo) has been given to the patients.   
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CHAPTER SIX 
CONCLUSION 
  
 
The study was comprised of two phases: Phase 1 the “Muscle Adverse Effect Survey”, 
and Phase 2 the “CoQ10 for Muscle Cramps Study”. The first phase of the study, the 
Muscle Adverse Effect Survey, was conducted at 45 community pharmacies in WA. 
From the 920 participants enrolled into the survey, 356 (38.7%) returned the 
questionnaire. Two hundred and five of the 356 (57.6%) respondents, 111 men and 94 
women, reported muscle symptoms.  Amongst the respondents with muscle symptoms, 
73 (35.6%) reported their muscle symptoms had worsened on using statins. Assuming 
non-respondents did not suffer from muscle problem reduced the overall incidence of 
potential statin-induced myopathy to 73/920 or 7.93%. It was reported that atorvastatin 
was the most commonly prescribed statin (59.3%), followed by simvastatin (29.8%), 
then pravastatin (10.4%) and fluvastatin (0.6%). Despite the high use of atorvastatin, the 
incidence rate of myopathy by atorvastatin users was found to be similar with other 
statins. The most common muscle symptoms were night cramps (54.6%), muscle aching 
(52.7%), and fatigue (49.3%), while the most commonly affected area of the body was 
the calves (62%). 
 
Statistical analysis with Multiple Logistic Regression showed increase in age, heart 
failure and the use of cortisone-like drugs increased the risk of myopathy among statin 
users. It was found that for every 1-year increase in age, the odds of suffering from 
myopathy increased 1.039 (95% CI 1.019 – 1.061).  Furthermore, taking cortisone-like 
medication increased the odds of suffering myopathy 16.4 times (95% CI; 2.2 – 124.3), 
while participants with heart failure were 9.3 times (95% CI 1.2 – 73.2) more likely to 
develop muscle symptoms when prescribed statins. 
 
The second phase of the study, Coenzyme Q10 for Muscle Cramps Study, was a single 
blind, placebo-controlled, cross over, 6-week evaluation of the benefits CoQ10 in 
reducing muscle cramps amongst statin and non-statin users.   
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It was found that on average, that statin users experienced a significant reduction in the 
severity of their muscle cramps, as indicated by lower average pain scores, during the 
period they were on CoQ10 (mean score = 6.36 ± 0.75) compared with placebo (7.37 ± 
0.85; p = 0.028). Furthermore, patients also experienced significantly shorter cramp 
duration when they were on CoQ10 (4.88 ± 0.84) than on placebo (5.84 ± 0.84; p = 
0.001). In contrast, amongst non-statin users (who were used as controls), there were no 
significant differences between CoQ10 and placebo efficacy in all assessed variables. 
 
This study revealed that muscle symptoms were common among statin users, 
particularly those suffering from heart failure, taking corticosteroids, and increasing in 
age. Furthermore, the administration of CoQ10 100 mg per day was safe and effective in 
reducing severity and duration of muscle cramps amongst statin users. However, these 
later findings need to be confirmed by larger, double blind, placebo controlled studies. 
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Appendix C 
PARTICIPANT INFORMATION SHEET 
 
Title: Coenzyme Q10 for Muscle Cramp Study 
School of Pharmacy 
Curtin University of Technology 
GPO Box U1987 
PERTH WA 6845 
 
Participation in this study is entirely voluntary and you are under no obligation to do so. 
Please take your time to make your decision. Discuss it with your family and friends. Be 
sure to ask questions about anything you don’t understand. 
 
WHO IS DOING THE STUDY? 
Investigator :  Mr. Dede Indra Kurniawan  
Supervisor   :  Mr. Jeff Hughes 
           
The Investigator and Supervisor are from School of Pharmacy, Curtin University of 
Technology. 
 
WHY IS THIS STUDY BEING DONE? 
The purpose of the study is to investigate the efficacy of coenzyme Q10 in reducing 
muscle cramp amongst statin and non-statin users. It is known that cholesterol-lowering 
medications that are called statins (the generic names are atrovastatin, fluvastatin, 
pravastatin and simvastatin) reduce coenzyme Q10 blood levels, which may influence 
energy production. Since muscles need coenzyme Q10 to meet energy demands, a 
decline in the coenzyme Q10 levels may contribute to impaired muscle function.  
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
Seventy (70) people with muscle cramps will take part in this study; thirty-five (35) 
statin users (Group A) and thirty-five (35) non-statin users (Group B).  
 
HOW LONG WILL I BE IN THIS STUDY? 
You will be in the study for 6 weeks, and you can stop participating at any time. If you 
want your information removed from the study this will be done.  
 
WHAT IS INVOLVED IN THE STUDY? 
If you take part in this study, you will be required to: 
a) Sign the Consent Form after you have read the Patient Information Sheet and 
send it together with Muscle Adverse Effects Survey questionnaire to the 
Investigator using the pre-paid envelope provided. The Investigator will contact 
you within 72 hours of receiving your Consent Form. 
b) You will be required to come to the research centre at the School of Pharmacy, 
Curtin University of Technology, to meet the Investigator.  He will explain to 
 114
you in detail the study design and answer any questions that you may have at that 
time. As part of the study you will receive a diary to record any muscle cramps 
you experience during the study.  
c) The first week of the study will be a lead-in period, during which time you will 
not be given any medication for your muscle cramps and you will be asked to 
record all muscle cramps experienced, including the time they occurred, their 
duration, severity and location. 
d) During the second and third weeks you will be assigned to receive either a daily 
treatment of coenzyme Q10 100 mg or a placebo (inactive substance). You are 
asked to take the medicine once daily at night. Again you will be asked to record 
all muscle cramps experienced during the trial, including the time they occurred, 
their duration, severity and location. You will also be asked to record any other 
symptoms, which you experience during the study. 
e) The fourth week will be a washout period during which time you will not be 
given any medicine for your cramps, and as in the previous week, you are asked 
to record the history of your muscle cramp in your diary. 
f) During the fifth and six weeks, you will be given by the Investigator either co-
enzyme Q10 or a placebo to take daily. You will, once again, be asked to record 
the history of your muscle cramps and to record any other symptoms during this 
period. 
g) At the end of the study, the Investigator will collect your diary. You will be 
interviewed about any possible side effects that you may suffer from the trial. 
You will be given the opportunity to receive a copy of the results of the study. 
 
WHAT ARE THE POSSIBLE SIDE EFFECTS, RISKS AND DISCOMFORT OF 
THE STUDY? 
Coenzyme Q10, known as ubiquinone, is a naturally occurring enzyme in the human 
body. The safety of coenzyme Q10 has been evaluated, and there is no serious toxicity 
associated with the doses in the range of 100 mg to 1,200 mg per day (this study will use 
the minimal dose, 100 mg per day). The side effects of coenzyme Q10 are commonly 
mild, and may include nausea, stomach upset, heartburn, loss of appetite, rash and 
fatigue. These side effects are usually resolved without the need of any treatment.  
 
ARE THERE BENEFITS TO TAKING PART IN THE STUDY? 
Taking part in this study may help in reducing your muscle cramp problem, and your 
participation may also lead to knowledge that will help others. 
 
WHAT ABOUT CONFIDENTIALITY? 
All data collected during the study will be treated strictly confidentially. On the 
completion of the study, all participants’ data will be de-identified, preventing anyone 
from identifying those people who participated in it. All results of the study will be 
grouped, and no reference will be made to any individual patient. Data from the study 
will be kept in a locked cupboard in the office of the Investigator at the School of 
Pharmacy, Curtin University of Technology. Only the Investigator and his Supervisor 
will have access to the data. 
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WHAT ARE THE COSTS? 
There will be no cost incurred in participating in the study. 
 
WHAT ARE MY RIGHTS AS A RESEARCH PARTICIPANT? 
Taking part in this study is voluntary. You may choose not to take part or may leave the 
study at any time without penalty.  
 
For the protection of the rights of participants in this study, the Human Research Ethics 
Committee of Curtin University of Technology has reviewed this research project. 
The Investigator will tell you about any new information that may affect your health, 
welfare, or willingness to stay in this study. 
 
WHO DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
If you have any questions about the study, you should contact: 
 
DEDE INDRA KURNIAWAN AT THE SCHOOL OF PHARMACY, CURTIN 
UNIVERSITY OF TECHNOLOGY ON 0421378098 
 
 
WILL I FIND OUT THE RESULTS OF THE STUDY? 
You will be offered the opportunity to receive a copy of the results of the study. 
 
Any person with complaints about the conduct of a research study can contact the 
secretary of the Human Ethics Committee, Curtin University of Technology, on 
(08) 92662784 
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Appendix D 
CONSENT FORM 
 
Coenzyme Q10 for Muscle Cramp Study  
School of Pharmacy 
Curtin University of Technology 
GPO Box U1987 
PERTH WA 6845 
 
 I, __________________________________hereby voluntarily consent to participate in 
the study entitled “Coenzyme Q10 for Muscle Cramp Study”. This study is being 
conducted by Mr. Dede Indra Kurniawan from the School of Pharmacy, Curtin 
University of Technology. 
 
I understand that any of the data collected for the purpose of this study will remain 
strictly confidential and not be used to identify any participant. I have been informed 
that the information obtained from this research may be used in future research or 
published. 
 
I have read the information sheet explaining this research in which details of the study 
have been clearly explained by the researcher. I am aware of the purpose of this project 
and what my involvement entails. My participation is entirely voluntary. 
 
I have been informed of my right to question any part of the procedure or withdraw from 
the project at any time. 
 
Name__________________________________ 
Address________________________________ 
_______________________________________
_______________________________________
_______________________________________ 
Phone__________________________________ 
 
 
Signature_______________________________ 
Date___________________________________ 
 
Any person with complaints about the conduct of a research study can contact the 
secretary of the Human Ethics Committee, Curtin University of Technology, on (08) 
92662784 
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Appendix E 
MUSCLE ADVERSE EFFECTS SURVEY 
 
INTRODUCTION 
Dear Patient, 
Muscle aches and pain are common and may be associated with many conditions. 
They may also be associated with the use of a range of medications. This survey is 
being undertaken to assess types and severity of muscle complaints which may be 
related to cholesterol lowering therapy. Statins are a group of cholesterol-lowering 
medications [for example atrovastatin (Lipitor®), fluvastatin (Lescol®, Vastin®), 
pravastatin (Pravachol®) and simvastatin (Zocor®, Lipex®)]. These are known to 
cause muscle complaints, such as muscle pain, weakness and cramps. However, how 
common these problems are amongst patients in general use is unknown. With this 
background, would you consider taking a few minutes to complete a questionnaire 
about your experience with statins and any muscle symptoms you may have? After 
completing the questionnaire, please return it to your pharmacist or via post to the 
Investigator using the return paid envelope provided. Dependent on your responses 
to the survey questions, you may be eligible to participate in the COENZYME Q10 
FOR MUSCLE CRAMP STUDY (further details are provided at the end of the survey 
questionnaire). The information obtained from this survey will be analyzed to 
determine the nature and frequency of statin-related muscle problems, and to identify 
any factors (age, sex, other diseases, etc) which may make statin users more prone 
too them.   If you think of questions or you would like to talk to the Investigator after 
filling out this survey, please feel free to contact me or my Supervisor, Mr. Jeff 
Hughes at the School of Pharmacy, Curtin University of Technology.  
 
Sincerely yours, 
 
Investigator : Mr. Dede Indra Kurniawan   Contact number: 0421378098. 
Supervisor   : Mr. Jeff Hughes   Contact number: 9266 7367  
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QUESTIONNAIRE 
1) Please TICK which of the following cholesterol-lowering medications that you 
take.  
 
Drug Name Strength Dose Duration 
 Atorvastatin 
     (Lipitor®) 
 ___tablet(s) per day  Less than 6   
months 
 6-12 months 
 More than 1 year 
 Fluvastatin 
       (Lescol®,Vastin®) 
 ___ capsule(s) per day  Less than 6 
months 
 6-12 months 
 More than 1 year 
 Pravastatin 
       (Pravachol®) 
 ___tablet(s) per day   Less than 6 
months 
 6-12 months 
 More than 1 year 
 Simvastatin 
       (Lipex®, Zocor®) 
 
 ___tablet(s) per day   Less than 6 
months 
 6-12 months 
 More than 1 year 
 Cholestyramine 
       (Questran Lite®) 
 
 ___ sachet(s) per day  Less than 6 
months 
 6-12 months 
 More than 1 year 
 Colestipol 
       (Colestid®) 
 
 ___ sachet(s) per day  Less than 6 
months 
 6-12 months 
 >1 year 
 Fenofibrate 
       (Lipidil®) 
 
 ___tablet(s) per day  Less than 6 
months 
 6-12 months 
 More than 1 year 
 Gemfibrozil  
       (Ausgem®, 
Gemhexal®,  Jezil®, 
Lipazil®, Lopid®) 
 ___tablet (s) per day   Less than 6 
months 
 6-12 months 
 More than 1 year 
 Ezetimibe 
       (Ezetrol®) 
 
 ___tablet(s) per day  Less than 6 
months 
 6-12 months 
 More than 1 year 
 Nicotinic Acid 
 
 ___tablet(s) per day  Less than 6 
months 
 6-12 months 
 More than 1 year 
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 Another lipid-
lowering 
medicine, 
please mention 
it 
____________
____________ 
 
 ___tablet(s)/capsule(s)
/sachet(s) per day 
 Less than 6 
months 
 6-12 months 
 More than 1 year 
 
2) Do you suffer from any following diseases?             Yes          No 
If yes, please TICK the conditions you suffer from. 
 Diabetes mellitus 
 Hypertension 
 Heart attack 
 Heart failure 
 Hypothyroidism  
 Kidney failure  
 
3) Do you take any of the following medications?        Yes           No 
If yes TICK which one in the table below, and complete the other details 
 
Drug Name Strength Dose Duration 
  Diltiazem 
(Cardiazem®, 
Coras®, 
Diltahexal®, 
Dilzem®, 
Vasocardol®) 
 
 ___tablet(s)/capsule(s) 
per day 
 Less than 6 
months 
 6-12 months 
 More than 1  
year 
  Nifedipine 
(Adalat®, Adefin®, 
Adefin XL®,  
Nifecard®, 
Nifehexal®, 
Nyefax®) 
 
 ___tablet(s)/capsule(s) 
per day 
 Less than 6 
months 
 6-12 months 
 More than 1 
year 
 Verapamil 
(Anpec®, Isoptin®, 
Verahexal®, 
Cordilox®, 
Veracaps®) 
 ___tablet(s)/capsule(s) 
per day 
 Less than 6 
months 
 6-12 months 
 More than 1 
year 
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4) Do you currently take or have you taken in the past any of the following? (You 
may TICK more than one) 
 
 Alcohol (more than 2 drinks 
daily) 
 Amiodarone  
 Antimalarial drugs 
 Carnitine 
 Chemotherapy for cancer 
 Colchicine   
 Coenzyme Q10 / Ubiquinone 
 Cyclosporin   
 Cortisone 
 Labetolol   
 Prednisone/steroids 
 Protease Inhibitors for AIDS 
 Thyroid preparations 
 Sodium valproate   
 Vitamin D   
 Vitamin E 
 Warfarin   
 
        
 
5) Please TICK any of the following muscle symptoms that you suffer from (or add 
your own). 
 None          Please go to Question 19  
 Cramp at night 
 Cramp after exercise 
 Muscle aching or soreness 
 Fatigue or tiredness 
 Muscle weakness (like trouble rising from a chair or mounting stairs) 
 Breathlessness with exercise 
 Another muscle symptom, please list ____________________________ 
 
6) Which muscle(s) hurt most? 
 Calves  
 Thighs and buttocks 
 Back 
 Arms 
 All muscles hurt equally 
 Another part of body, please list _________________________ 
 
7) How would you describe the frequency of you muscle symptoms? 
 Constant throughout the day 
 Comes and goes throughout the day 
 Appears at particular times of the day (Please state when 
________________) 
 
8) If you suffer from leg-cramps, how often to these occur? 
 Every day 
 At least once a week 
 At least once a month 
 Other (Please state frequency ________________) 
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9) How long have you had your muscle symptoms? 
 Less than 1 month 
 1-12 months 
 1 – 5 years 
 More than 5 years 
 
10) Since commencing this therapy how would you describe you muscle symptoms 
(consider both the frequency and severity of your symptoms)? 
 
 No change     Please go to Question 12 
 Better   Please go to Question 11  
 Worse   Please go to Question 11 
 
11) If your muscle symptoms have got better or worse, what has changed? 
 Frequency 
 Severity 
 Frequency and severity 
 Other, please list _____________________________________ 
 
12) Do your symptoms improve off statin therapy? 
 Yes 
 No  
 Do not know 
 
13) Have you ever had any following laboratory tests? 
Please TICK the appropriate answer for each test. 
Test Yes No Do not know 
Liver function test    
Creatine kinase    
Myoglobinuria    
 
14) Are you currently taking either of the following minerals alone or as part of a 
mixed mineral supplement? 
 
 Calcium  
 Magnesium 
 
15) Is there any family history of muscle disorders? 
 Yes 
 No 
 
16) Does your urine appear dark or tea colored after exercise or fasting? 
 Yes 
 No 
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17) Have you discussed your muscle symptoms with your general practitioner or 
specialist? 
 Yes 
 No 
 
18) Does your general practitioner or specialist believe that your symptoms are 
related to your statin therapy? 
 Yes 
 No 
 
19) Please enter the following demographic information: 
Age :   _________ years 
Sex :  Male 
 Female 
 
 
Thank you very much for your cooperation. 
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Appendix F 
THE LIST OF PHARMACIES PARTICIPATED IN 
MUSCLE ADVERSE EFFECT SURVEY 
 
 
  
No Name of Pharmacies No Name of Pharmacies 
1. Stirling Village 24. Bayley St 
2. Pemberton 25. Inglewood Amcal Chemist and News
3. Albany Amcal Chemist 26. Beverley 
4. Chemmart Central 27. Helena State 
5. Kingsley Village 28. Warnbro Fair Chemist 
6. Thomas & Co Chemist 29. Pharmacy 149 
7. Augusta 30. Wellness on Walcott 
8. Lynwood 31. Pharmacy 777 Bayswater 
9. Higa Wyombe 32. Pharmacy 777 Mt Hawthorn 
10 Guardian Pharmacy Craigie 33. Pharmacy 777 Cottesloe 
11. Victoria Park 34. Pharmacy 777 Spearwood 
12. Toodyay 35. Pharmacy 777 Whitford City 
13. Forrestfield Amcal Chemist 36. Pharmacy 777 Glendalough 
14 Gnowangerup 37. Pharmacy 777 Maylands 
15. Northam 38. Pharmacy 777 Applecross 
16. Murdoch 39. Pharmacy 777 Hilton Centre 
17. Usher 40. Pharmacy 777 Karratha 
18. Friendlies Chemist Subiaco 41. Pharmacy 777 Midland 
19. Emslie’s Floreat 42. Pharmacy Help Cottesloe 
20. Ashburton Village Chemist 43. Laurie Keys 
21. Friendlies Chemist Leederville 44. West Busselton Pharmacy 
22. Centrepoint Amcal Chemist 
23. Thornlie Square 
45. East Victoria Park 
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Appendix G 
SAMPLE DIARY OF A PARTICIPANT FROM COENZYME Q10 
FOR MUSCLE CRAMPS STUDY 
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Appendix H 
 POSTER PRESENTATION  
 
This study was presented at the following conference:  
The Annual Conference of Australasian Pharmaceutical Science Association (APSA) in 
Adelaide, on 3rd December 2006. 
 
 
TITLE: HOW COMMMONLY DO STATIN-USERS SUFFER FROM MUSCLE 
SYMPTOMS? 
Dede Indra Kurniawan, Dr. Jeff Hughes, Prof. Moyez Jiwa 
School of Pharmacy, Curtin University of Technology, Bentley Western Australia, 6102. 
 
Background: Muscle aches and pain are common and may be associated with many 
conditions including the use of drugs. Statins are a group of cholesterol-lowering 
medications known to cause muscle complaints, such as muscle pain, weakness and 
cramps.  
 
Aims: The aims of this study were to assess the frequency and nature of muscle 
symptoms amongst statin users and factors, which may influence them. Methods: The 
study was undertaken in 46 community pharmacies in WA. Patients taking statins were 
asked to complete a questionnaire, which had been adopted from a myopathy survey of 
IMPOSTER (Is Myopathy Part of Statin Therapy?). Statistical analysis of data was 
performed using the SPSS statistical software package for Windows, version 13.0.  
 
Results: Of the 920 patients enrolled into the study, 356 (38.7%) returned their 
questionnaire. Of these 205 (111 men and 94 women; 57.6%) had muscle symptoms. 
Assuming, non-responders did not suffered from muscle symptoms then the overall 
incidence was (22.3%; 205/920). Amongst respondents with muscle symptoms 73 
(35.6%) reported worsening on using statins. Atorvastatin was the most commonly 
prescribed statin (59.3%), followed by simvastatin (29.8%), pravastatin (10.4%) and 
fluvastatin 0.6%. Despite the higher use of atorvastatin, the incidence rate of myopathy 
by atorvastatin users was found to be similar with other statins.  The most commonly 
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reported muscle symptoms were night cramps (54.6%), muscle aching (52.7%) and 
fatigue/tiredness (49.3%), while the most commonly affect area of the body was the 
calves (62%). Apart from statin use, age and other drugs being taken (e.g. cortisone and 
prednisone) were associated with increased risk of myopathy. 
 
Conclusion: Muscle symptoms were common amongst statin users, and appeared more 
common in those taking corticosteroids and in the elderly. 
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Appendix I 
ORAL PRESENTATION 
 
This paper was presented at the following conference: 
The Australian Society for Medical Research (ASMR) Week Symposium in Perth, on 7th 
June 2007, and was awarded The InvitrogenTM Award for the Best Presenter. 
 
TITLE: COENZYME Q10 FOR MUSCLE CRAMPS STUDY  
Dede Indra Kurniawan, Dr. Jeff Hughes, Prof. Moyez Jiwa 
School of Pharmacy, Curtin University of Technology, Bentley Western Australia, 6102. 
  
Background: Muscle cramps are one of the adverse affects suffered by 
hypercholesterolemia patients who are treated with statin. Besides reducing cholesterol 
levels, statins also reduce coenzyme Q10 blood levels. One of several hypotheses of 
pathophysiology for statins- inducing muscle cramps are reduced level of coenzyme 
Q10. Besides being a very important antioxidant, coenzyme Q10 also functions as a 
transmembrane proton conductor and an electron carrier between NADH and succinate 
dehydrogenases and the cytochrome system, which is needed for phosphorylation of 
ADP into ATP. Therefore, a decrease in the coenzyme Q10 tissue levels, as reflected in 
its reduced blood levels, may contribute to the muscle function impairment.  
  
Aims: The aims of this study were to investigate the efficacy of oral coenzyme Q10 
supplements in reducing muscle cramps in statin users and non-users.  
 
Methods:  Coenzyme Q10 for Muscle Cramps Study was a single blind, placebo-
controlled, cross over trial of CoQ10. Participants were separated into two groups: 
Group A was those who suffered from muscle cramps who were taking statins; and 
Group B was those who suffered from muscle cramps but not taking statins. The trial 
consisted of four phases: a 1-week assessment period, during which the baseline 
frequency of muscle cramps was assessed; a 2-week treatment period, during which 
participants of Group A were allocated coenzyme Q10 100 mg per day, and Group B 
were allocated placebo; a 1-week wash out period, during which participants did not 
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take either coenzyme Q10 or placebo; and then a second 2-week of the second treatment 
during which participants of Group A took placebo, and Group B took CoQ10 100 mg 
per day. Patients were given a diary to record days on which cramps were experienced, 
the number of cramps suffered per day, the average and maximum pain scores 
associated with cramps, the duration of the cramps, the part(s) of body affected by the 
cramps, and any adverse reactions suffered over the duration of the study for the entire 6 
weeks.  Statistical analysis of data was performed using the SPSS statistical software 
package for Windows, version 13.0.  
 
Results:  It was found that on average, participants on Group A (statin users) 
experienced significant lower average pain scores associated with cramps during the 
periods they were on CoQ10  (mean score = 6.36 ± 0.75) than on placebo (7.37 ± 0.85), 
with t(29)= -2.316, p=0.028. Furthermore, patients also experienced significant shorter 
cramp duration when they were on CoQ10 (4.88 ± 0.84) than on placebo (4.88 ± 0.84), 
with t(29)= -3.535 , p=0.001. On the contrary, in Group B (non-statin users or controls), 
there were no significant differences between CoQ10 and placebo efficacy in all 
assessed variables. 
 
Conclusion:  the administration of CoQ10 100 mg per day was safe and effective in 
reducing severity and duration of muscle cramps amongst statin users 
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Appendix J 
 
BRIEF EXPLANATION: 
REPEATED MEASURES ANOVA 
FOR THE UNINITIATED 
 
 
 
Repeated Measures Analysis of variance (ANOVA) is an approach to help us deal with 
individual differences. These differences usually are part of the error term. Since they 
increase the error term, they decrease the likelihood of finding a significant result. While 
individual differences reflect actual differences among individuals, they also reflect the 
individual’s state when the instrument was administrated, environmental factors, and 
response style. With repeated measures ANOVA, we may be able to measure, thus 
control, some of this variation.  
 
There are two main types of repeated measures designs (also called within-subjects 
designs). One type involves taking repeated measures of the same variable(s) over time 
on a group or groups of subjects. For example, if we were studying hypertension, we 
would probably want more than one blood pressure reading on our subjects.  
 
The other main type of repeated measures designs involves exposing the same subjects 
to all levels of the treatments. This often called using subjects as their own controls. For 
example, we wanted to test medications to reduce nausea during chemotherapy. We 
could randomly assign individuals to one of the following three conditions: medication 
one, medication two, or control. 
 
However, if our participants varied widely in the amount of nausea they experienced, the 
within-subject variability would be larger because F statistic is based on the ratio of 
between-group variance to within-group variance, there would have to be a very large 
between-group difference to attain a significant result; that is, the large variability 
among the subjects could obscure any real differences between groups. One way to 
remove these individual differences would be to assign each subject to all treatments. 
Each participant would be exposed to medication one, medication two, and the control 
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condition in random order. Each participant would serve as his or her own control, and 
the within or error variance would be decreased. This would result in a more powerful 
test and would decrease the number of subjects needed for the study. 
 
The basic assumption for independent ANOVA and repeated measures ANOVA also are 
almost the same. The dependent variable should be normally distributed, and the 
homogeneity of variance requirement should be met. However, there is one major 
difference where with independent ANOVA; the observations are independent of each 
other, which are achieved by randomly assigning participants to mutually exclusive 
groups. With repeated measures ANOVA, however, there is correlation between the 
measures because they are from the same people. Therefore, the assumption of 
compound symmetry (also known as sphericity) must be met.  
 
There are two part of the assumption. The first part is the assumption that the 
correlations across the measurements are the same. The second part of the assumption is 
that the variances should be equal across the measurements. With three measurements 
(medication one, medication two, and control), the variance of 1 = variance of 2 = 
variance of control. If data violate the sphericity of the assumption, there are several 
corrections that can be applied to produce a valid F-ratio, such as the Greenhouse-
Geisser correction and the Huynh-Feldt correction.  
 
Source: Munro, B. Statistical Methods for Health Care Research. 3ed. Philadelphia, 
New York: Lippincott; 1997.  
 
 
 
 
 
 
 
 
